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1. Introduct ion 
The pathogenetic relevance of T-cells in autoim- 
mune disorders, of which human rheumatoid arthritis 
(RA) is the commonest, has long been recognized. 
Excellent papers summarize the findings in support 
of the T-cell paradigm in RA [1-6], while others 
have challenged the centrality of T-cells, pointing at 
macrophages and/or  fibroblasts as villains, at least in 
some aspects of the disease [7,8]. The present paper 
reports on some recent clinical and experimental 
contributions in the fields of immunogenetics, T-cell 
receptor usage, and cytokine patterns that give new 
momentum to the T-cell hypothesis and may help 
integrating previous observations regarded as con- 
flicting. As in other autoimmune diseases, the evi- 
dence of arthritis as an antigen-driven process is 
gaining credit [9-11], with the implication that, once 
the (auto)antigen should be identified, the search for 
disease-relevant T-cells may be facilitated; it may 
then be possible to manipulate or deviate the specific 
T-cell response against he (auto)antigen [12-15], in 
the reasonable hope to eradicate the autoimmune 
process, before irreparable articular damage occurs. 
1.1. Clinical features of  rheumatoid arthritis 
RA is a chronic inflammatory disease of unknown 
etiology, with a genetic predisposition mapping to 
genes of the major histocompatibility-II system 
(MHC-II) [16,17]; environmental factors, however, 
must also play a role, since the concordance among 
monozygotic twins does not exceed 23% (reviewed 
in [18]). The long-term severity and relatively high 
incidence of the disease (approx. 1% worldwide) 
render it a serious problem for its human and social 
costs. RA is characterized by recurring flares of 
painful joint inflammation, followed by tissue de- 
struction at the cartilage-pannus junction and in the 
subchondral bone [2,19,20], which eventually leads to 
deformities and loss of articular function; RA, how- 
ever, should be considered a systemic disorder [19] 
which includes serological/hematological signs of 
inflammation, subcutaneous rheumatoid nodules, high 
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levels of circulating rheumatoid factor (immuno- 
globulin M, G, and A binding to the Fc part of IgG; 
[21]), vasculitis, and granulomatous and/or intersti- 
tial organ pathologies. In addition, lymphoid organs 
such as spleen, bone marrow, and lymph nodes are 
involved in the Felty's syndrome, a rare but severe 
form of RA [22]. Furthermore, an often severe wast- 
ing syndrome can ensue, which, together with other 
systemic features, leads to increased mortality [23,24]. 
1.2. Morphological and immunohistochemical fe - 
tures of the inflamed synovial membrane 
The synovial membrane (SM) of RA patients is 
characterized by thickening of the lining layer and 
inflammatory infiltration of blood-derived macro- 
phages [25] and T-cells [26,27]. Fibroblasts of local 
origin also contribute to hyperplasia in the SM; to- 
gether with macrophages, they are believed to medi- 
ate most of the tissue destruction, once the inflamma- 
tory cascade has initiated (reviewed in [7]). On aver- 
age, T-cells constitute between 30 and 50% of all 
synovial cells [8,28,29]. Their numbers and pheno- 
typic features, however, are unequally distributed in 
different areas of the inflamed SM ([1,30-34]]; Fig. 
1D); variable ratios of CD4-positive (commonly de- 
fined as helper T-cells) versus CD8-positive (i.e., 
cytotoxic) T-cell subsets are present also in synovial 
effusions ([3,34-37], Fig. 1C) and peripheral blood 
([34,35,38], Fig. 1B). As a net result, the relative 
proportions of these populations are highly variable 
in different compartments (Fig. 1). In addition to 
A Normal  B lood 
T-cells N 80% of all lymphocytes 
CD4 + 49% 
CD8 + 29% 
CD4 + : CD8 + = 1.7 
B RA Blood (slight lymphopenia) 
T-cells ,~ 80% of all lymphocytes 
CD4 + 58% 
CD8 + 23% 
CD4 + : CD8 + = 2.5 
C RA Synovia l  F lu id 
T-cells ~ 80% of all lymphocytes 
CD4 + 43% 
CD8 + 39% 
CD4 + : CD8 + = 1.1 
D RA Synovial Membrane 
Transit ional  Area 
(T__andB _lymphocYte s /t ~Q.)) \ 
CD4 + 36% I 
CD8 + 44% I 
CD4 + : CD8 + = 0.8 ~, 
T-cells N 80% of all lymphocyte 
CD4 + 63% 
CD8 + 22% 
CD4 + : CD8 + = 2.9 
[Adapted from (35)] [Adapted from (30)] 
Fig. 1. Compartmental distribution of CD4-positive and CD8-positive T-cell subpopulations in rheumatoid arthritis patients. Panels B and 
C show the relative distribution of blood and synovial fluid T-cell subpopulations in comparison with blood of healthy individuals (A) 
[3,34-37]. While in RA patients there is a slight lymphopenia (B), the frequency of CD4-positive T-cells is significantly elevated, and 
that of CD8-positive cells significantly decreased, resulting in a high CD4:CD8 ratio (approx. 2.5) in comparison with normals (approx. 
1.7). In the synovial fluid, in turn, (C) the ratio of CD4:CD8 T-cells is approx. 1, due to an excess of CD8-positive cells in comparison 
with 'arthritic' and normal peripheral blood [35]. D is a schematic representation of the histopathological configuration of the T-cell 
infiltrate in the synovial membrane (SM). In lymphoid aggregates forming around small vessels, structures that render the SM comparable 
to immunologically stimulated peripheral lymphoid organs [42], T-cells represent 80% or more of the lymphocytes [30]. The CD4-positive 
subset of T-cells dominates in these aggregates [1,31,34], whereas T-cells carrying the CD8 phenotype are significantly under-represented 
[340,341]; this is reflected in a high CD4:CD8 ratio (2.9). In transitional areas, where T-cells are less numerous and intermingle with 
macrophage-like c lls [1,28,30], the CD8-phenotype predominates [1,28,30], with a low CD4:CD8 ratio (0.8). Thus, the ratios of CD4- 
and CD8-positive T-cells are highly variable; this points to differential, possibly opposite immune responses in various compartments of
the same disease [30,40]. 
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these 'constitutional' differences, anti-rheumatic 
treatments, whether or not selective for T-cells, in- 
duce profound modifications of the relative propor- 
tions of T-cell subpopulations in the synovial tissue 
[39]. Such degree of complexity renders very difficult 
the interpretation f the role of T-cells in arthritis, as 
well as their therapeutic manipulation. 
Useful insights into the role of CD4- and CD8- 
positive cells derive from the comparison of RA with 
other chronic inflammatory disorders [30,40]. The 
histological/phenotypical configuration of CD4-posi- 
tive T-cell-rich lymphoid aggregates in the RA SM 
(Fig. 1D) is similar to the tuberculoid, less active 
form of leprosy; in contrast, a prominence of CD8- 
positive T-cells and macrophages, as seen in the 
transitional areas of the RA SM (Fig. 1D), would 
resemble the active lepromatous form of leprosy (re- 
viewed in [30] and [40]). A similar bias towards 
CD8-positive T-cells is also seen in the inflammatory 
infiltrate of rejected kidney transplants (reviewed in 
[30]). Thus, histologically different areas of the in- 
flamed SM may differentially contribute to single, 
perhaps even opposite aspects of the disease. 
1.3. The activated phenotype of synovial T-cells 
the view that the SM is an immunologically active 
site [44], suggesting that antigen-driven responses 
involve both T- and B-cells. 
Paradoxically to the T-cell activation paradigm, 
however, synovial or peripheral blood T-cells isolated 
from RA patients react very poorly against mitogens 
[45], recall antigens [37,38,46], or exogenous IL-2 
[47,48]. RA patients also display poor T-cell medi- 
ated delayed-type hypersensitivity responses (DTH) 
to common recall antigens [49]. These features are 
particularly prominent in patients with very severe 
joint disease, and define a subset of 'anergic' patients 
who, interestingly, respond particularly well to anti- 
T-cell therapy [46,50]. 
Thus, from the histopathological configuration of 
synovial T-cell subpopulations (Fig. 1 D), the sys- 
temic aspects of the disease (Fig. 1 B), and the 
paradoxical T-cell dysfunction, there emerges one 
fundamental feature in RA: there are different T-cell 
subsets in play, and activation may regard disease- 
promoting as well as disease-regulating T-cells. Any 
potential anti-T-cell treatment that should not dis- 
criminate at least between these two tendencies would 
be bound to inefficacy or severe drawbacks. 
Rheumatoid synovial T-cells display markers of 
cell activation, both recent and long-term (Table 1), 
in fact more so than RA peripheral blood T-cells [29], 
a feature fundamental to the hypothesis that RA 
results from T-cell immunity against self-antigens 
contained in the joint [1,2,19,41,42]. The presence of 
plasma cells organized in germinal center-like struc- 
tures [43], which produce as much immunoglobulin 
as peripheral lymph nodes [21], also contributes to 
2. T-cell activation in the course of immunological 
responses 
Both the histopathological onfiguration (Fig. 1 D) 
and the status of activation of T-cells (Table 1) in the 
SM, i.e., at the primary site of inflammation, have led 
to the hypothesis that RA is a local, antigen-driven 
process [1,41,42]. Since a causative infectious agent 
Table 1 
Activation markers present on the surface of T-cells infiltrating the synovial membrane and their functional significance 
Reference Marker Functional significance 
[28,31,34,83,342,343] HLA-DR 
[29,34,83,92,97] 
[34,83,344] 
[92,97] 
[34,83] 
[3] 
[345] 
[77,81] 
IL-2 receptor (on a minority of T-cells) 
Very late activation antigens (VLA) 
CD45RO (on the majority of T-cells) 
CD69 antigen 
UM4D4/CDw60 
CD2R variant of CD2 antigen 
CTLA-4 and B7 (B7-1 ;CD80) 
(1) Product of MHC-II system in genetic linkage to RA [17] 
(2) Expressed late and long-lastingly on T-cells following 
antigen stimulation [85] 
Very recent activation [82] 
Adhesion molecules [344] 
Acquisition of antigen-specific memory [87,88] 
Very recent activation, involved in intracellular signaling [84] 
Surface component of a T-cell activation pathway [3] 
Down-regulated onanergic T-cells [346] 
Second signal ligand molecules 
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has never been identified (reviewed in [18] and [51]), 
the autoimmune nature of the synovial inflammation 
has gained credit over the years. How autoimmunity 
ensues has been a major focus of research in the last 
decade, enjoying and at the same time stimulating 
major advancements in the understanding of basic 
features of immunology. Therefore, before entering 
the details of T-cell activation in RA, some funda- 
mental features characterizing antigen-driven im- 
munological responses are outlined (Fig. 2). 
Cytokine 
production 
Thl IFN'7 
IL-2 
IL-4 
Th2 IL-5 
IL-10 
~ J  Clonal 
expansion Formation of 
memory 
Expression 
of 
activation 
markers 
Fig. 2. Representation f the 'immunological synapse' [52] involved in antigen (Ag) recognition. Antigenic peptides processed by 
antigen-presenting cells (APC) are presented on the cell surface within the groove of a major histocompatibility complex (MHC) 
molecule. T-cells bind their specific antigen through a T-cell receptor (TCR), which recognizes the bimolecular complex of antigen/MHC 
molecule. Recognition is dictated by the amino acid sequence of a and /3 chains in the case of o~/3 T-cells (95% of peripheral T-cells. 
reviewed in 54), or 3' and 6 chains in the case of 3,6 T-cells (1-5% of peripheral T-cells, reviewed in [55]), which in humans carry 
neither the CD4 nor the CD8 co-receptor. The relationship between APC and T-cells appears univocal, in that T-cells carrying the CD4 
co-receptor recognize pitopes presented by MHC-II molecules, whereas T-cells with the CD8 co-receptor recognize pitopes presented 
by MHC-I molecules (reviewed in [58]). In parallel to antigen binding (first signal), ligation of second-signal ligand pairs on both APC 
and T-cells are required for full T-cell activation (second signal). Upon full activation (indicated by the jagged arrow), the 
TCR-associated CD3 molecule initiates intracellular signaling, triggering the activation cascade (see Section 2.3 and Section 2.4 for 
details): (1) expression of surface activation markers (see Table 1 for details); (2) expression of differentiation markers acting as adhesion 
molecules, which favour entry of T-cells at sites of inflammation; (3) expression of the differentiation marker CD45RO, indicating 
formation of antigenic memory; (4) lymphokine production, with commitment to a Thl pro-inflammatory- or a Th2 regulatory pathway, 
depending on the nature of the antigenic stimulus and the microenvironment i  which antigen recognition occurs; (5) clonal expansion, 
with formation of T-cells bearing the same phenotypic/functional characteristics of the mother cell, i.e., antigen specificity and 
uniqueness of the T-cell receptor [86]. 
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2.1. Antigen presentation and recognition (first sig- 
nal) 
Antigen-driven T-cell activation results from inter- 
action of different components within a functional 
unit, called by some 'immunological synapse' [52] to 
stress the intercellular, multiple, interdependent re- 
ceptor-ligand interaction occurring when a T-cell en- 
counters its specific antigen (Fig. 2). 
In normal immune responses, T-cells are engaged 
in specific recognition of antigens, initiation of pow- 
erful defense, and formation of antigenic memory to 
improve defense upon repeated contact with the anti- 
gen (reviewed in [53]). For this purpose, they are 
equipped with a highly specific surface antigen-re- 
ceptor, the T-cell receptor, a surface molecule of the 
immunoglobulin family consisting of disulfide-linked 
heterodimers of ce and /3, or T and 6 subunits, 
capable of selective recognition of one or a few 
peptides (reviewed in [54,55]; Fig. 2). 
The unique antigen-complementarity determining 
region within the T-cell receptor is formed during the 
course of T-cell maturation by gene rearrangement 
for the ol and /3 chains (or y and 6 chains, respec- 
tively), leading to a steric configuration that confers 
specificity for antigen recognition (reviewed in [56]). 
Although dual T-cell receptors can exist on the sur- 
face of individual T-cells [57], the concept of T-cell 
mono/oligospecificity remains a fundamental as- 
sumption for the understanding of specific immune 
responses. 
On the surface of T-cells, the T-cell receptor is 
coupled to the CD3 molecule (Fig. 2), which on one 
hand controls the surface expression of the T-cell 
receptor, and on the other hand transmits intracellular 
signals upon binding of the T-cell receptor to its 
specific antigen (reviewed in [58]). 
T-cells recognize antigenic peptides in the context 
of appropriate MHC-complex molecules (reviewed in 
[59] and [60]; Fig. 2). Antigen-presenting cells, such 
as dendritic ells [61], macrophages [59], B-cells [62], 
synovial fibroblasts [63], or even activated T-cells 
themselves [64,65] can process antigenic determi- 
nants from exogenous microorganisms or autologous 
proteins by proteolytic digestion, and subsequently 
express the antigenic peptide within the groove of a 
MHC molecule on their surface (Fig. 2); this confor- 
mational groove owes its restriction for certain pep- 
tides to particular amino acid sequences of subunits 
of the MHC molecule [17,56]. 
Functionally, thus, the specificity of antigen recog- 
nition is dictated in parallel by MHC molecules 
preferentially presenting certain antigenic peptides 
(reviewed in [17] and [56]), and by T-cell receptors 
recognizing only given MHC/antigen complexes 
(Fig. 2). 
Accessory molecules on the surface of T-cells 
determine the quality of the T-cell effector esponse 
[58]. The CD4 or CD8 molecules are critical in this 
sense (reviewed in [58,66]): acting as true co-recep- 
tors (Fig. 2), the presence of one or the other deter- 
mines whether the T-cell recognizes determinants 
presented by MHC-class II, or MHC-class I 
molecules, respectively (reviewed in [58]). Because 
of this strict correspondence, antigen presentation by 
MHC-I molecules results in engagement of CD8- 
positive T-cells, whereas antigen presentation by 
MHC-II molecules will engage CD4-positive T-cells 
(reviewed in [58]). 
2.2. Second signal in T-cell activation 
With the probable advantage of protecting the 
organism against inappropriate, random T-cell activa- 
tion, full activation of resting and memory T-cells 
will not proceed unless second signals are provided at 
the moment of antigen recognition (reviewed in [67- 
71]; Fig. 2). Second signals consist of ligand pairs on 
both the T-cell and antigen-presenting cells that be- 
come an integral part of the 'immunological synapse', 
such as CD28 and B7-1/B7-2 (or CD80/86; [70,72]) 
or combinations of particular cytokines uch as IL-1 
and IL-6 [73]. 
Evidence has grown that second signals exert a 
decisive role in directing the immune response: if 
cognate second signals are missing, T-cells become 
by default anergic or apoptotic upon antigen recogni- 
tion, representing a mechanism whereby tolerance to 
self constituents can be accomplished [70]. In animal 
studies, moreover, subtypes of second signals (B7-1 
or B7-2) appear to dictate whether Thl or Th2 re- 
sponses will be elicited in CD4-positive T-cells, i.e., 
responses characterized by secretion of pro-in- 
flammatory or regulatory cytokines, respectively 
([74], reviewed in [75]), therefore containing the po- 
tential for initiating or rather controlling (auto)im- 
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mune processes. Thus, if the progression of RA, in 
particular the initiation of recurrent flares, should 
depend on waves of activation/re-activation of aive 
and memory T-cells, second signals could play a 
decisive role throughout the disease and be exploited 
as targets of therapy. Indeed, second signal ligand 
pairs, such as CD28 or CTLA-4 on the T-cell side 
and B7-1 or B7-2 on the antigen presenting cell 
[76-78], have been detected in the inflamed RA 
synovial tissue. However, as the full complexity of 
the second signal system is just being unraveled, with 
indications for an inhibitory role of some of the 
molecules involved ([77], reviewed in [79]), the role 
of individual molecules in RA remains to be estab- 
lished [80,81]. 
2.3. Effector responses of T-cells following antigen- 
driven activation 
Antigen recognition in the presence of second 
signals results in a cascade of distinct signal transduc- 
tion events (reviewed in [58]) that lead to different 
T-cell effector esponses. 
(a) Expression of activation markers (Fig. 2, Table 
1, right column), the constellation of which provides 
information about the time point in which T-cell 
activation has occurred, i.e., CD69 and IL-2 receptor 
testify for a very recent event ([82-84], Table 1), 
whereas MHC-II molecules are less immediately but 
long-lastingly upregulated ([83,85], Table 1). 
(b) Secretion of lymphokines (reviewed in [52]; 
Fig. 2), which creates the appropriate microenviron- 
ment favouring both specific responses and engage- 
ment of additional pro- or anti-inflammatory cells to 
the site of inflammation. To warrant hese complex 
tasks, distinct T-cell subsets produce lymphokines in
a polarized fashion [52], with pro-inflammatory Thl- 
cells producing IFN-y and IL-2, and regulatory Th2- 
cells producing IL-4, IL-5, IL-10, and others (exem- 
plified in Fig. 2). 
(c) Antigen-specific lonal expansion, which, in 
case of infection, leads to ubiquitous amplification of 
the host immune defense. A distinct property of the 
clonally expanded T-cells is, by definition, the iden- 
tity of their T-cell receptor [86]. 
(d) Formation of memory function, whose acquire- 
ment is documented by expression of isoforms of the 
CD45 surface molecule (CD45RO; [87,88], Fig. 2 
and Table 1). The presence of this marker distin- 
guishes memory T-cells from naive T-cells, which 
instead carry a CD45RA-positive phenotype [89-91]. 
2.4. Acquirement of migratory capacities by activated 
T-cells 
The constellation of surface characteristics ac- 
quired by activated T-cells is very important, since it 
dictates their migration patterns and eventually their 
retention at inflammatory sites [91-93]. In fact, 
knowing the prerequisites necessary for T-cell immi- 
gration into peripheral organs [94-96] has led to an 
important correction of the view that because high 
numbers of T-cells infiltrate the rheumatoid syn- 
ovium, they must all necessarily be engaged in au- 
toimmunity, i.e., recognition of an autoantigen [4,97]. 
Circulating lymphocytes migrate from blood ves- 
sels to inflammatory sites depending on the expres- 
sion of homing receptors on their own surface and on 
the presence of so-called 'addressins' on tissue en- 
dothelial cells [93,98]; the efficiency of this process 
depends on the constellation and/or upregulation of 
activation markers: due to their surface expression of 
lymphocyte function associated antigen-1 (LFA-1) 
and very late activation antigens (VLA; [91]), 
CD45RO-positive memory T-ceils immigrate more 
easily than CD45RA naive T-cells. Memory T-cells, 
however, do not need to be recently activated in order 
to enter the inflamed site [99], but they have random 
access (i.e., independent of their antigen specificity) 
if addressins are up-regulated on tissue endothelial 
cells, for example because of pre-existing inflamma- 
tory pathology [93]. Because this non-specific mecha- 
nism of T-cell infiltration operates also in RA [100], 
only a minority of synovial T-cells may be engaged 
in recognition of potential (auto)antigens [4,101]; in 
fact, their bystander (or 'frustrated activation' status; 
[97]) may explain the surprising paucity of T-cell-de- 
rived cytokines observed in the synovial compart- 
ment (see below; [6,7]). 
2.5. Autoimmunity, antigen-specificity, and spreading 
of autoimmuni~ to cryptic determinants 
A basic re-definition of the role of T-cells in 
recognition of (auto)antigens stems from the observa- 
tion that autoimmunity propagates in a temporal fash- 
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ion. Several models of autoimmunity are initially 
characterized by oligoclonal expansion of T-cells 
specific for immunodominant epitopes of autoimmu- 
nity-eliciting proteins, i.e., epitopes that elicit a strong 
and sudden response [102]. Soon, however, there is 
spreading of the T-cell response to a number of latent 
or cryptic determinants, i.e., segments of the anti- 
genic protein that under normal circumstances do not 
elicit T-cell responses [102-106]. The segregation of 
latent portions of antigenic proteins may be perturbed 
as a consequence of tissue pathology; in case of 
inflammation, for example, pro-inflammatory cy- 
tokines can lead to disclosure of cryptic determinants, 
inasmuch as they can affect enzymatic pathways 
within the professional antigen-processing cell, or 
recruit non-professional antigen-presenting cells that 
cleave the antigen differently [105]. The end result 
would be generation of sufficient quantities of latent 
peptides to become immunogenic [106] and, thence, 
propagation of autoimmunity to non-immunodomi- 
nant peptides. 
In general, the role of proteolytic pathways in 
different antigen-processing cells [107], and/or the 
intrinsic incapability of these cells to generate all 
possible antigenic peptides of self-proteins under 
physiological conditions [108,109], are being recog- 
nized as some of the factors that shape the repertoire 
of antigenic peptides against which tolerance devel- 
ops, and therefore against which autoimmunity may 
ensue, removing some emphasis from T-cells as the 
only possible villains in autoimmunity [110]. 
In turn, the concept of autoimmunity spreading to 
different epitopes of the same antigen, or to com- 
pletely different antigens, bears the important conclu- 
sion that, in long-standing or even fairly recent RA, 
T-cell expansion but no sharp T-cell oligoclonality 
may be found at the primary site of pathology. This, 
together with non-specific immigration of T-cells, 
may contribute to a 'dilution' of the synovial tissue 
T-cell repertoire that renders difficult the identifica- 
tion of T-cells that initiate or sustain autoimmune RA 
[111]. 
2.6. Tolerance and breakage of tolerance 
The immunological constitution of each individual 
is such that self-constituents are respected by the 
immune system; accordingly, all antigens encoun- 
tered by T-cells are sorted in two major categories: 
self-antigens, against which T-cells will act toler- 
antly; and non-self antigens, which will elicit an 
immunological response. Clinically relevant autoim- 
munity, whichever the cause, ensues when this basic 
'code' is disrupted. Tolerance and autoimmunity, 
however, should not be viewed as completely oppo- 
site processes; on one hand, in fact, the definition of 
tolerance xtends to ignorance of antigens never be- 
fore presented to the immune system (see above); on 
the other hand, low-grade (i.e., clinically irrelevant) 
autoreactivity of T- and B-cells is found in normal 
individuals [40,112]. 
Tolerance to self-constituents is acquired during 
ontogenic and maturational development of T-cells in 
the thymus [reviewed in 53, 86, 113]. It is believed 
that while non-self reactive T-cell clones are posi- 
tively selected to guarantee defense against foreign 
constituents (reviewed in [53]), negative selection 
eliminates T-cells that show high-affinity recognition 
of self-antigens (reviewed in [86] and [113]). Toler- 
ance is achieved through complex and multiple pro- 
cesses such as clonal (i.e., antigen-specific) deletion 
in the thymus, and clonal anergy or clonal ignorance 
in the periphery [86,105,113]. While in the case of 
clonal deletion autoreactive T-cells are physically 
eliminated via apoptosis and cannot be reactivated, 
anergic and/or functionally ignorant T-cells can be 
resumed to recognize (auto)antigen under particular 
circumstances, for example in excess of certain cy- 
tokines and/or their combinations [105,114]; one 
possibility is the sudden availability of a previously 
hidden, unaccessible antigen at an immunologically 
privileged site, or else the surge of otherwise cryptic 
determinants at levels exceeding the threshold of 
tolerance [106]. Such disclosure, in turn, can ensue 
during or following tissue pathology, may it be trau- 
matic or infectious [ 113,115,116]. 
Another mechanism that acts to maintain toler- 
ance, and may therefore be broken in case of autoim- 
munity, is active suppression [40,117,118]; in this 
case, low-affinity autoreactive T-cells are present, but 
their response to antigen recognition is actively 
down-regulated by other T-cells. Applied to the ne- 
cessity of controlling autoimmune B- and T-cells in 
normal individuals, regulatory T-cells have been im- 
plicated in keeping the balance between low-grade 
natural autoimmunity and its proper control [40,112]. 
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3. T-cells in rheumatoid arthritis 
3.1. Immunogenetic susceptibility to human rheuma- 
toid arthritis and the 'shared epitope' hypothesis 
As seen in Fig. 2, the specificity of an immune 
response is a two-sided process that regards both 
antigen-presenting cells and T-cells; if RA is an 
antigen-driven disease, it is to be expected that partic- 
ular features of antigen presentation will greatly af- 
fect T-cell involvement in this disorder. 
As mentioned, up to 70-80% of RA patients in 
different geographical areas display an association 
with HLA-DR or HLA-DQ loci of the MHC-II com- 
plex [5,16,17,119,120], with predominance of certain 
alleles that act as independent susceptibility genes 
[17,121,122]. Interestingly, even if different HLA- 
haplotypes are involved, they all share a short amino 
acid sequence (reviewed in [17] and [123]). These 
findings have led to the formulation of the so-called 
'shared epitope' hypothesis [ 121 ], according to which 
the subtle configuration of the hypervariable region, 
common to several MHC-II products linked to dis- 
ease susceptibility, selects peptide fragments that will 
be presented to antigen-specific CD4-positive T- 
helper cells; upon completion of the (MHC-II/anti- 
gen/T-cel l  receptor)-trimolecular complex (Fig. 2), 
selected CD4-positive T-cells with autoimmune po- 
tential may become activated and clonally expanded, 
with subsequent initiation of a pro-inflammatory cas- 
cade. Interestingly, homozygosity for some HLA- 
DRB1 alleles seems to confer a higher degree of 
severity and/or  systemic involvement to the disease 
[122,124], although this issue is not completely set- 
tled [125]. Increased severity may be 'dose-depen- 
dently' related to the density of MHC-II molecules 
on antigen-presenting cells, determining the extent o 
which disease-relevant CD4-positive T-cells are en- 
gaged in the pathological process. 
While the role of individual HLA-DR and/or  
HLA-DQ molecules in RA is currently under debate, 
i.e., whether they hold a disease-promoting or rather 
a protective role (see [126] for details), important 
experimental evidence in support of the interrelation- 
ship between the genetic constitution of the HLA 
system and restricted response of CD4-positive T-cells 
in determining autoimmune arthritis has been very 
recently provided by Nabozny et al. [123]. Mice 
deficient for their own MHC system were made 
transgenic for genes encoding the a- and /3-chain of 
the human HLA-DQ8 molecule. Unlike transgene- 
negative littermates, HLA-DQ8-transgenic animals 
became polyarthritic upon immunization with bovine 
collagen II; the disease was paralleled by develop- 
ment of anti-bovine collagen II antibodies cross-reac- 
tive with mouse collagen, and formation of collagen- 
II-responsive CD4-positive T-cells in the lymph 
nodes. Likewise, transgenic expression of human/  
mouse chimeric o~- and /3-chains of the HLA-DR4 
molecule in MHC-II deficient mice conferred suscep- 
tibility to experimental llergic encephalomyelitis in 
otherwise resistant mice [127]. 
In this immunogenetic model of the pathogenesis 
of RA it becomes clear that intervention of T-cells, 
though crucial to the development of RA, is flanked 
and likely even preceded by a skewed MHC-II reper- 
toire in antigen-presenting cells. In this case, CD4- 
positive T-cells would be forced to play rather the 
accomplice than the villain role, although, under 
particular conditions, activated T-cells not only ex- 
press molecules of the MHC-II system (see Table 1), 
but can also become ffective antigen-presenting cells 
[64,65]. Whichever the case, the identification of 
relevant polymorphic MHC-II genes related to the 
development of human RA now offers the perspec- 
tive to single out specific antigenic peptides calling 
for complementary, specific CD4-positive T-cells 
[128,129]; this bears the obvious implication that. 
once the antigen(s) should be identified, it may be- 
come possible to identify and therapeutically ablate 
(auto)antigen-specific T- ells, thereby silencing au- 
toimmunity before extensive articular damage takes 
place. 
3.2. Binding of peptides to MHC molecules 
In view of the two-sided character of antigen 
recognition (Fig. 2), considerable progress has been 
recently made in defining the rules determining the 
affinity of a given peptide for particular MHC 
molecules and the resulting probability of this peptide 
to be found in the antigen-binding roove of this 
MHC molecule (reviewed in [128-130]). These stud- 
ies have on one hand established the positions of the 
antigen-binding groove of the MHC molecule critical 
for the binding of antigenic peptides, and of the 
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influence that characteristic amino acid sequences 
exert on peptide binding [128]; on the other hand they 
have allowed to predict whether peptides of candidate 
autoantigens can bind to known disease-susceptibility 
MHC-II molecules [ 131], or to directly elute peptides 
from the MHC-II molecules of RA patients [132]. 
These analyses have selected peptides of potential 
autoantigens, such as calreticulin, against which au- 
toantibodies are detected in human RA [132], or the 
Epstein-Barr virus-encoded nuclear antigen-1 
(EBNA-1), which shows high homology with colla- 
gens and keratins [133]. 
In multiple sclerosis, in which the candidate au- 
toantigen myelin basic protein is implicated in the 
pathogenesis of the disease, and in which T-cell 
clones with well-defined antigen-specificity have been 
identified [134-136], a very elegant approach has 
recently been used to single out peptides of viral or 
bacterial origin recognized in a cross-reactive fashion 
by antigen-specific T-cells [137]. Based on peptide 
motifs that take into consideration the requirement 
for binding to both the T-cell receptor and the MHC-II 
molecule, several Epstein-Barr viral peptides were 
found, some of which strongly stimulated T-cell 
clones reactive against myelin basic protein [137]. 
These results indicate that there exist T-cells capable 
of cross-recognition of (auto)antigens and 
viral/bacterial peptides; consequently, molecular 
mimicry between self- and foreign constituents as a 
potential cause of autoimmunity can now be experi- 
mentally addressed. 
In pemphigus vulgaris, in turn, an autoimmune 
disorder directed most likely against he junctional 
protein cadherin, disease susceptibility on the basis of 
the MHC-II configuration may boil down to a change 
from an acidic to a basic residue in one important 
anchor position of the MHC-II molecule (reviewed in 
[129]). 
In the case of RA, fine analyses of short peptide 
sequences with the potential to cause autoimmunity 
are not yet possible, since the causing (auto)antigen(s) 
remain(s) unknown, and its/their identification may 
require large screening not only of synovial antigens, 
but also of antigens ystemically available; this ne- 
cessity is emphasized by some evidence of clonotypi- 
cally expanded T-cells not only at the primary site of 
pathology, but also in peripheral blood (see below, 
[138-142], Table 2). 
3.3. Do antigen-specific T-cell responses underlie 
rheumatoid arthritis ? 
The conventional strategy of isolating T-cells with 
(auto)antigenic specificity from the primary site of 
pathology has been applied in RA, upon the reason- 
able assumption that instigating antigens must be part 
of normal or disease-related joint tissue constituents 
[41]. 
To date, however, only a few T-cell clones have 
been isolated that react against he major cartilage 
component collagen type II [143-145], or cartilage 
proteoglycans [146], and some of them have also 
been isolated from the peripheral blood of healthy 
individuals [147]. More recently, T-cell clones with 
reactivity against the heavy chain of immuno- 
globulins, i.e., the equivalent of B-cells producing 
rheumatoid factor, have been derived from the syn- 
ovial fluid of RA patients [148]. Interestingly, each of 
the antigen-specific clones bore a different T-cell 
receptor, indicating that the response against a given 
protein sequence can be polyclonal instead of oligo- 
clonal; also, this antigen was found to be recognized 
in the context of HLA-DR, possibly HLA- 
DRBI* 0401 [148], complying thus with the criterion 
of disease susceptibility association [ 17,119]. 
The search for (auto)antigen-specific T-cell clones 
in human RA has profited from the discovery that 
Mycobacterium-induced adjuvant arthritis in the rat is 
based on T-cell reactivity to the 180-188 fragment of 
the 65 kD mycobacterial heat shock protein (re- 
viewed in [149]). In RA patients, Holoshitz et al. 
[150] documented increased T-cell reactivity to an 
acetone-precipitable fraction of Mycobacterium tu- 
berculosis that was cross-reactive with cartilage. This 
was confirmed by Res et al. [151], who showed high 
reactivity of RA synovial fluid T-cells to the 65 kD 
mycobacterial heat shock protein, and also docu- 
mented that reactivity was inversely correlated with 
the duration of the disease, the latter finding in 
keeping with the concept of time-dependent profiles 
of T-cell autoreactivity [102,103]. More recently De 
Graeff-Meeder et al. [152] have documented specific 
T-cell autoreactivity against he human 60 kD homo- 
logue of the mycobacterial 65 kD heat shock protein 
in patients with juvenile RA, whereas Quayle et al. 
[153] have made the observation that, in early RA, 
synovial fluid o~/3-T-cell receptor CD4-positive T- 
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cells recognize 2 adjacent peptides of the 65 kD 
mycobacterial heat shock protein, each showing high 
homology to the human 60 kD heat shock protein; 
notably, the HLA restriction of these responses was 
not identical, encompassing the possibility that the 
two peptides may initiate different effector esponses. 
Disappointingly, however, T-cell reactions to heat 
shock proteins are found also in patients with non-RA 
arthritis [154]. 
The findings relating to heat shock proteins, al- 
though as yet inconclusive, are important in that they 
fuel the concept of molecular mimicry between bac- 
terial and self-constituents a  a cause of autoimmu- 
nity. Heat shock proteins are immunogenic and highly 
conserved throughout bacterial and mammalian 
species. This makes it theoretically possible that a 
bacterial infection first elicits normal immunological 
responses to bacterial heat shock proteins. Because 
tissues under inflammatory stress up-regulate the pro- 
duction of endogenous heat shock proteins, and be- 
cause of the sequence homology between bacterial 
and human heat shock proteins, the immune response 
may subsequently turn against self heat shock pro- 
teins, triggering autoimmunity in genetically predis- 
posed individuals. Since it is hardly conceivable that 
all infections trigger autoimmunity, it may be that 
select bacteria/viruses, for example those eliciting 
complex and chronic immune responses, are particu- 
larly prone to induction of autoimmunity [40]. 
3.4. T-cell receptor usage and oligoclonality of T-cells 
Since the search for (auto)antigen-specific T- ells 
has proven a formidable task, several investigators 
have turned to a different strategy for the identifica- 
tion of disease-relevant T-cells in synovial compart- 
ments, based on both a better understanding of how 
T-cells recognize antigen within the MHC-groove of 
antigen-presenting cells, and on the availability of 
sophisticated molecular biology techniques (indicated 
in Table 2). Reasoning that synovial T-cells may be 
oligoclonally expanded due to recognition of 
(auto)antigen(s), many groups have undertaken a
painstaking hunt for T-cell clones that carry a unique 
rearrangement of genes for T-cell receptor a/3, or y6 
chains (Table 2). 
The results of this major effort, however, are not 
univocal; many, but not all studies, have found at 
most evidence of limited heterogeneity of the Va or 
Vfl gene usage in the RA SM or synovial fluid 
([11,139,155-172], Table 2); of these, some could 
document oligoclonal T-cell expansion ([11,138- 
140,155,157,162,163,165,168-170,173-177], Table 
2), and that mainly in patients who showed preferen- 
tial expansion of certain Vfl families ([11,155,157, 
162,163,165,168-170]; Table 2). In addition, oligo- 
clonal expansion of synovial T-cells was more obvi- 
ous in T-cell clones responsive to IL-2 ([176,178]; 
Table 2), conceivably those expressing IL-2 receptors 
upon very recent activation ([82], Table 1, Fig. 2), 
although such an expansion procedure bears the risk 
of in vitro growth selection. Moreover, the preva- 
lence of certain V/3 families clearly depended on 
phase and duration of RA ([161,169], Table 2). 
The expression of sequence motifs in the comple- 
mentarity-determining region 3 (CDR3) of the T-cell 
receptor, the area devoted to binding of the MHC- 
II/antigen complex, has also been compared in 
oligoclonal synovial T-cells; a remarkable sequence 
homology at key amino acid positions has emerged in 
different T-cell clones obtained from the synovial 
tissue [11,170,179]. Further molecular dissection of 
the CDR may result critical in the identification of 
autoantigenic peptides in RA. Thus far, the results 
indicate that a common epitope of a candidate 
(auto)antigen may be recognized by more than one 
clonally expanded T-cell population at the site of 
inflammation. 
In contrast, the involvement of antigen-specific 
T-cell receptors has been clearly documented by the 
expansion of Vfl genes in experimental collagen-in- 
duced arthritis [180-183] a model which, similarly to 
RA, develops in linkage to selected haplotypes of the 
Ia subregion of the MHC system and presents with 
Ia-restricted activation of collagen II-specific T-cells 
[184]. 
The lack of clear-cut results in the study of the 
T-cell receptor in RA is also somewhat in contrast 
with the results so far obtained in multiple sclerosis, 
in which a biased T-cell receptor gene usage within 
brain lesions appears pecific for myelin basic protein 
peptides [ 134-136,185], in analogy with similar find- 
ings in experimental llergic encephalomyelitis [ 186], 
the animal model for multiple sclerosis. Accordingly, 
mice transgenic for the a/3 T-cell receptor recogniz- 
ing the immunodominant epitope of myelin basic 
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protein develop spontaneous chronic myelitis in some 
cases, or severe xperimental encephalomyelitis upon 
challenge with antigen and/or adjuvant [187]. 
Signs of restricted T-cell receptor usage and/or 
oligoclonality in RA can thus be singled out mostly 
from a minority of T-cells positive for the IL-2 
receptor, i.e., recently activated T-cells ([176,178], 
Table 1 and Fig. 2); although these results may be 
biased by in vitro growth selection, the limited T-cell 
involvement is consistent with the very low figure of 
IL-2-receptor-positive- or blast T-cells in synovial 
tissue [30,34,188-190], a configuration i  which T- 
cells are expected to be if undergoing antigen-specific 
activation/proliferation (Fig. 2). These low figures 
also correspond to the paucity of T-cells expressing 
IFN-y or IL-2 message in situ (see below; reviewed 
in [6] and [7]). It is thus conceivable that autoreactive 
T-cells hide among IL-2-receptor-positive T-cells, 
supporting the view that a very small fraction of de 
novo activated T-cells, whether recognizing the initial 
(auto)antigen or new antigens/epitopes via spread- 
ing, may suffice to maintain chronicity and/or reiter- 
ate disease flares in RA [4]. 
3.5. Evidence for T-cell expansion at a systemic level 
In earlier studies (Table 2), there was no consistent 
matching between synovial and circulating T-cell 
clones [138,160], supporting the hypothesis that acti- 
vation and oligoclonal expansion occur locally in the 
SM, i.e., at the primary site of inflammation. 
However, interesting data in favour of systemic 
T-cell activation in RA are emerging most recently. 
Applying some constraints o the experimental design 
[191], i.e., (1) recent onset arthritis hould be investi- 
gated, since it may more easily refer to the original 
(auto)antigen before autoimmunity spreads to cryptic 
determinants; and (2) patients must be selected on the 
basis of their RA susceptibility genes, Goronzy et al. 
[169] found clonally expanded CD4-positive T-cells 
with a predominant V/33, Vfll4, and V/317 gene 
rearrangement of the T-cell receptor both in periph- 
eral blood and synovial fluid. Interestingly, the fre- 
quency of clonally expanded Vfl 17-positive/CD4- 
positive T-cells fluctuated in the same patients over 
time, a feature which may explain the inconsistency 
among different studies on T-cell receptor usage (Ta- 
ble 2). Using cell sorting by flow cytometry rather 
than molecular techniques, Zagon et al. [171] docu- 
mented expansion in peripheral blood not only of 
CD4-positive-, but also of CD8-positive T-cells with 
a dominant V/317 rearrangement. Finally, selecting 
T-cells on the basis of their Vfl gene usage, Waase et 
al. [142] identified a minute subset of oligoclonally 
expanded, CD4-positive T-cells in HLA-DR4-posi- 
tive RA patients. Interestingly, expansion was evident 
also in HLA-matched, unaffected siblings, suggesting 
that a particular genetic background may reflect in 
less effective regulation of T-cell responses. The 
expanded clonotypes bore a CD4-positive/CD28- 
negative phenotype in circulation (but a CD4-posi- 
tive/CD28-positive phenotype in the SM), and they 
were functionally active in recognition of potential 
autoantigens [141]. 
While monitoring the fate of peripheral blood T- 
cells following treatment with the T-cell depleting, 
anti-pan-leucocyte monoclonal ntibody CAMPATH- 
1H in RA patients, Jendro et al. [139] have docu- 
mented reconstitution of CD4-positive/CD45RO- 
positive memory T-cells with a restricted T-cell re- 
ceptor Vfl chain usage; the emergence of dominant 
clonotypes in the peripheral blood suggested that 
T-cell re-population occurred through clonal prolifer- 
ation of surviving T-cells at systemic sites. Of note, 
the T-cells reappearing in the SM in coincidence with 
clinical recurrence of the disease were enriched in 
clones similar to those emerged in the peripheral 
blood upon re-population; more recent studies appear 
to confirm the match between peripheral nd synovial 
clonotypes [140,142]. 
While the evidence for systemic involvement of 
T-cells is still relatively meager, it is on the other 
hand remarkable that clear clonal expansion can be 
observed at all in the blood compartment, given that 
circulating T-cells represent only 2% of the whole 
body T-cell pool [192]. The functional significance of 
activated T-cells in circulation is nonetheless unclear. 
The apparent reset created by anti-T-cell treatment, 
i.e., depletion of circulating T-cells and initial de- 
crease of tissue pathology [139], could be hypotheti- 
cally assimilated to very initial stages of RA. In this 
case, gradual clonotypic expansion i  peripheral blood 
and subsequent colonization of the SM (which then 
undergoes a disease flare), might mean that antigen 
priming of disease-relevant T-cells occurs elsewhere 
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than in the SM, i.e., at systemic sites (see path A of 
Fig. 3). The stimulus dictating retention of primed 
T-cells in the SM, in this case, would be molecular 
mimicry and cross-reactivity with self-epitopes highly 
expressed in the joint. But, since signs of very recent 
activation of T-cells, however limited to a few cells, 
are clearly documented in the SM ([29,34,83,176, 
178]; Table 1) it is also possible that priming of 
disease-causing T-cells occurs locally and systemi- 
cally in parallel [83]. On the other hand, the signifi- 
cance of T-cell oligoclonality in RA needs to be more 
thoroughly addressed, in particular in comparison to 
other chronic autoimmune or infectious disorders. 
Also, it is still unclear whether extraarticular manifes- 
tations of RA are mediated by mere deposition of 
IgG-rheumatoid factor complexes or by the direct 
action of autoantibodies [122]; since there is as yet no 
clear evidence of a connection between oligoclonal 
T-cell expansion and induction of autoantibodies, the 
link between systemic signs of RA and systemic 
T-cell involvement remains therefore speculative. 
3.6. Is synouiotropism secondary to local infection? 
One of the fundamental, yet unresolved questions 
in autoimmunity is how a generic, genetically deter- 
mined susceptibility o autoimmune disorders eventu- 
ally results in selected, well-defined organ patholo- 
gies. 
In the case of RA, local infection as a triggering 
factor has been repeatedly hypothesized, in spite of 
the failure to isolate causative agents from the SM or 
fluid (reviewed in [51 ]). Recently, however, a number 
of findings have renewed the interest in this concept. 
First, the causative agent of Lyme disease, which 
includes a chronic arthritis similar to RA, has been 
identified in the Borrelia burgdorferi spirocheta (re- 
viewed in [193]); arthritis can also ensue as a severe 
side-effect of vaccination with bacillus Calmette 
Guerin [ 194]. Secondly, the inflamed rheumatoid SM 
expresses a 62-kD molecule recognized by antibodies 
against he EBNA-1 antigen of the Epstein-Barr virus 
[195]; also, there exists cross-reactivity between the 
major epitope of the EBNA-1 antigen and collagen 
[133]. Thirdly, some AIDS patients develop a form of 
chronic arthritis reminiscent of RA (reviewed in [196] 
and [197]), and arthropathy develops in patients in- 
fected with the retrovirus HTLV-1 [198]. Also, severe 
synovial alterations develop in goats infected with the 
caprine arthritis-encephalitis lentivirus (reviewed in 
[196]), or in mice transgenic for the HTLV-1 genome 
[199]. Indeed, virus-like particles appear to be present 
in the synovial fluid of RA patients [200], although 
these findings have not been confirmed [201]. Inas- 
much as retro- or lentiviruses harbour preferentially 
in fibroblasts and macrophages [202], and given that 
these cells show massive signs of activation in the 
RA SM (reviewed in [203]), the parallel involvement 
of immune and mesenchymal cells may be reconciled 
under the unifying hypothesis of a viral etiopathogen- 
esis. 
At an experimental level, in turn, notwithstanding 
that most experimental models of arthritis are in- 
duced with bacterial products (e.g., mycobacteria 
contained in complete Freund's adjuvant or strepto- 
coccal cell wall fragments; reviewed in [204]), infec- 
tion with Mycoplasma rthritidis does induce chronic 
arthritis in experimental nimals [205]. Finally, infec- 
tion can cause breakage of immunological tolerance 
and development of autoimmunity [ 115,116,206,207]; 
autoimmunity, in turn, does not ensue in pathogen- 
free conditions. Especially the latter findings stress 
that tissue pathology may disclose autoantigens oth- 
erwise sequestered from the immune system [105], 
and/or that particular self- and non-self epitopes may 
share sequences, in a way that immunity will turn 
into autoimmunity because of molecular mimicry and 
consequent cross-reactivity [137]. In this case, by the 
time self-perpetuating autoimmunity ensues, the etio- 
logical agent may have already cleared, explaining 
why synovial samples are aseptic [208]; T-cell activa- 
tion may nonetheless proceed, for example due to 
cross-reactive autoimmunity independent of the origi- 
nal agent. 
A post-infective cause of arthritis may also recon- 
cile with the view that initial T-cell activation must 
not necessarily, or not only, occur in the joint: T-cells 
may be primed at sites in which they first encounter 
bacterial or viral antigens, enter circulation, and sub- 
sequently home to synovial tissue in which they are 
re-activated and retained because of molecular 
mimicry. The evidence of cross-reactivity between 
mycobacterial ntigens and cartilage [150], or be- 
tween bacterial and self heat shock protein [153] may 
represent a basis for such hypothesis (Fig. 3). No- 
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tably, the acetone-precipitable fraction of mycobacte- 
ria induces up-regulation of the proliferating cell 
nuclear antigen (PCNA), an antigen that can be the 
target of autoimmunity, selectively in T-cells [209]; 
this provides further evidence for a possible link 
between infection and autoreactivity. 
It is to be expected that a molecular approach to 
the etiology of RA will provide some definite an- 
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swers, especially since, as mentioned before, com- 
mon viral and self sequences can now be identified if 
they meet the requirements of complementarity o
both the MHC-II-presenting molecule associated with 
disease susceptibility, and to the corresponding com- 
plementarity-determining re ion of the T-cell recep- 
tor [128,129]. Early studies based on such a rationale 
have already evidenced that the Epstein-Barr virus 
glycoprotein 110 is a candidate for such a role in RA 
[210]; similarly, in multiple sclerosis several 
Epstein-Barr viral peptides strongly stimulate T-cell 
clones reactive to myelin basic protein [137]. 
A novel view of possible etiopathogenetic factors 
of RA, which would confirm the importance of infec- 
tion as a prelude to autoimmunity, is based on the 
biased usage by T-cells of certain T-cell receptor V/3 
genes; this has raised the question whether microbial 
toxins defined as superantigens may be the cause of 
V/3 expansion in RA [155,171,211], since the T-cell 
response to such superantigens i dictated by a re- 
stricted V/3 gene usage [212]. Interestingly, the MAM 
superantigen derived from Mycoplasma arthritidis 
can exacerbate the disease upon intra-articular injec- 
tion [213]; similarly, other superantigens cause re- 
lapses in a number of experimental utoimmune dis- 
orders, including streptococcal cell wall-induced 
arthritis [214]. In experimental nimals, interestingly, 
the Mycoplasma rthritidis superantigen elicits ex- 
pansion of V/3 17-positive T-cells, the same that are 
expanded in many RA patients ([169,171]; Table 2), 
resulting in reactivity against Mycoplasma in as many 
as 5% of peripheral T-cells. Even more interestingly, 
this superantigen i duces not only polyclonal T-cell 
stimulation [215], but simultaneously a T-cell-depen- 
dent production of polyclonal immunoglobulin by 
plasma cells [216], features that remind of two basic 
characteristic of human RA, i.e., scarce oligoclonal 
T-cell expansion and coexistence of T- and B-cell 
activation. Another striking general feature of super- 
antigens is their capacity to generate T-cell anergy 
against different antigens [217]. Superantigens, there- 
fore, can potentially reproduce yet another feature of 
RA, the paradoxical coexistence of T-cell activation 
with T-cell anergy [38]. 
However, before drawing definite conclusions on 
the role of superantigens in autoimmunity, it should 
be kept in mind that a bias towards particular V/3 
families could be simply related to expansion of 
autoimmune T-cells (Table 2); also, there is only 
limited concordance among studies concerning possi- 
ble disease-relevant V/3 families (Table 2). Further- 
more, biased V/3 gene usage, with or without T-cell 
expansion, occurs also in non-autoimmune r sponses, 
for example in booster vaccination for hepatitis B 
[218], DTH responses to Mycobacterium leprae [219], 
and, in fact, even normal aging [220]. Anergy, in 
turn, cannot be used only in favour of the superanti- 
gen hypothesis, since it is associated to several hu- 
man pathologies, including viral or mycobacterial 
infections, or lymphoproliferative disorders (reviewed 
in [221 ]). 
3. 7. B-cell maturation as evidence of antigen-driven 
responses and T-cell/B-cell interaction 
Several lines of evidence indicate that immuno- 
globulin heavy and light chain genes in plasma cells 
show clear signs of antigen-driven selection in the 
Fig. 3. Hypothetical scheme of compartmentalization of T-cell activation i RA. Path A depicts the possibility that antigen recognition 
and priming of disease-triggering T-cells occur extrasynovially, forexample in lymphoid organs; in this case production oflymphokines, 
expression ofmarkers of recent T-cell activation, as well as oligoclonal expansion would be found in lymphoid organs, but hardly in the 
synovial membrane (SM); subsequently, T-cells would circulate in peripheral b ood carrying markers of activation, both recent and less 
recent (see Table 1), and specificity for the instigating antigen; homing and final retention i the SM would concern afraction of primed 
T-cells, possibly because of molecular mimicry between the instigating antigen and local arthritogenic epitopes. Path B depicts the 
alternative possibility that T-cells are activated in the SM. The available data contribute hus far to a general picture of limited T-cell 
activation i the SM, i.e., scarce lymphokine production [6,7] and limited oligoclonality [11,138-140,157,173-179], supporting therefore 
the scheme depicted inPath A. Data from systemic experimental arthritides, in turn, contribute othe view that lymph node T-cells, rather 
than synovial T-cells, are central to the development of arthritis ([240-243], own observation), also supporting the scheme in Path A. 
Clearly, this conclusion cannot be drawn in the case of human RA, since quantitative comparisons of lymphoid and synovial 
compartments are not available; some recent evidence of activation and/or clonotypic expansion of T-cells in peripheral blood 
([138-142,166,169-171], Table 2) would support the usefulness of such comparisons. However, it cannot be excluded that local and 
systemic T-cell activation coexist [83], for example due to reactivity to (auto)antigenic epitopes present both locally and systemically. 
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RA inflamed synovium [9,10]; both the enrichment of
particular kappa transcripts and the presence of nu- 
merous omatic mutations, particularly in the comple- 
mentarity-determining regions, indicate scape of un- 
usual subpopulations of B-cells from proper control 
by the immune system. Since in most instances B-cell 
activation relies on the help of T-helper cells, in 
terms of both surface ligand binding and cytokines 
necessary for proper B-cell function [222], an anti- 
gen-driven B-cell involvement in the synovial tissue 
provides indirect evidence of the central role played 
by T-helper cells in synovitis [44]. Accordingly, neu- 
tralization of the CD40 ligand gp 39, present on the 
surface of T-helper cells and devoted to T-cell/B-cell 
cooperation, does prevent he development of colla- 
gen-induced arthritis [223], a model in which promi- 
nent B-cell-mediated autoimmunity flanks T-cell in- 
volvement [reviewed in 204]. 
Indeed, one of the possible strategies to isolate 
synovial antigen(s) causing RA is to identify candi- 
date (auto)antigens that elicit on one hand the produc- 
tion of autoantibodies, and on the other hand the 
response of disease-relevant T-cells [224,225]. In re- 
cent onset synovitis (< 6 month duration, i.e., a time 
in which the effects of spreading of autoimmunity o
cryptic determinants may still be limited) serum im- 
munoglobulins recognize a limited set of candidate 
(auto)antigens present in the SM; among these are the 
IgG heavy and light chain dimer [226], providing a 
basis for the formation of rheumatoid factor. T-cell 
clones that proliferate in response to Ig heavy chains 
have also been isolated from arthritic joints [148], 
supporting thus the concept hat expansion of B- and 
T-cells in RA may be parallel and antigen-driven 
[44]. 
The presence and levels of rheumatoid factor, 
although not specific for RA, are of biological and 
clinical significance for this disease [19]. Interest- 
ingly, rheumatoid factor genes can be found also in 
normal individuals, in whom their expression is care- 
fully regulated (reviewed in [227]); rheumatoid fac- 
tor-positive B-lymphocytes, trategically located in 
the mantle zone of tonsils and lymph nodes, may 
capture spontaneously forming autoantibody-autoan- 
tigen complexes, and present hem as processed au- 
toantigen to T-cells [228]; in normals, this process 
may occur in a microenvironment that favours T-cell 
suppression, thus exerting a control over naturally 
occurring autoreactivity [227]. In the case of RA 
patients, then, not the mere presence of rheumatoid 
factor, but the paradoxically narrow range of rheuma- 
toid factor genes, would actually indicate lack of 
control of autoimmunity [227,229]; this situation 
would lead to expansion of non-suppressed autoreac- 
tive T-cells, and explain why rheumatoid factor-posi- 
tive RA patients display increased severity of the 
disease. 
3.8. The profile of T-cell-derived cytokines 
(a) Rheumatoid arthritis. The hypothesis that acti- 
vated T-cells play a primary role in arthritis has the 
corollary that if synovial T-cells are locally activated, 
they should express significant amounts of pro-in- 
flammatory Thl-type lymphokines (Fig. 2), namely 
IFN-y and IL-2 (reviewed in [52]), at the primary site 
of inflammation. 
Lymphokines of both Thl and Th2 type have 
indeed been detected in RA synovial tissue or fluid 
(reviewed in [7,230-234]); however the studies of 
their quantities and profiles have proven puzzling for 
a number of reasons. First, there is a very poor 
representation f IFN-y and IL-2 [7]. In situ, lym- 
phokine-positive c lls are very scarce; interestingly, 
they do not exceed the number of IL-2 receptor-posi- 
tive T-cells (reviewed in [6]), in line with the expecta- 
tion that only the minority of activated and not the 
bulk of bystander T-cells produce lymphokines. In 
contrast, macrophage-derived cytokines are over- 
whelming [7], which has led to a basic questioning of 
the central role of synovial T-cells in autoimmune 
synovitis [7] and to the alternative hypothesis that 
macrophages and/or fibroblasts could bear a major, 
active pathogenic role in RA, if not in initiating the 
disease, at least in maintaining it (reviewed in 
[7,8,203,235]). 
The second problem is that, while in vitro and in 
some in vivo systems it is possible to clearly discern 
between Thl- and Th2-responses [52], such sharp 
assignment is not possible in RA; in synovial tissue 
and/or SM-derived T-cell clones, in fact, lym- 
phokine profiles are a mixture of partial Thl- and 
Th2-responses [7,232], consistent with the histologi- 
cal and immunohistochemical heterogeneity of the 
RA synovial tissue (Fig. 1); in addition, there is 
expression of TGF-/3 [232,233], a multipotent cy- 
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tokine possessing anti-inflammatory properties at a 
local level [236]. Furthermore, some effector re- 
sponses potentially relevant o RA seem to obey to 
cell-cell contact between T-cells and neighbouring 
cells rather than to released lymphokines [237]. Find- 
ing certain cytokines, therefore, does not automati- 
cally reveal the quality and quantity of the function 
of their cell of origin, especially since surface-bound 
receptors, soluble receptors, or inhibitors with over- 
lapping affinities also contribute to the cytokine net- 
work [230]. 
The analysis of lymphokines in RA is further 
complicated by the influence of duration, severity, 
and phase of the disease. As anti-rheumatic herapies 
greatly affect the distribution of T-cells in the RA 
SM [39], it is likewise difficult to establish what can 
be assigned to the disease itself, and what to attempts 
of regulation or repair. 
(b) Experimental arthritides. To understand the 
degree and quality of T-cell activation in arthritis, as 
estimated by the production of lymphokines (Fig. 2), 
it is useful to recur to well-characterized animal 
models which have clearly defined time courses and 
can be studied without concurrent treatment 
([238,239], own studies). In collagen-induced and 
adjuvant arthritis, two models of systemic polysyn- 
ovitis, for example, mRNAs for T-cell-derived cy- 
tokines are poorly expressed in the SM (especially in 
comparison with macrophage-derived cytokines, 
-similarly to human RA), with a significant but fairly 
modest mount of synovial IL-2 mRNA only in corre- 
spondence with the peak of synovitis; in contrast, 
there is a clear IFN-y Thl response in the regional 
lymph node; of note, the IFN-y response precedes 
the clinical onset of synovitis, indicating that priming 
of disease-relevant T-cells in these models may be a 
lymph node rather than a synovial event (Fig. 3), as 
also envisaged in other studies [240-242]. In 
antigen-induced arthritis, in contrast, a model in which 
the arthritogen is directly injected into the articular 
cavity, both IFN-T and IL-2 are very highly ex- 
pressed in the SM [238]. Of note, in both systemic 
and local arthritides Th2 cytokines are also up-regu- 
lated acutely, fueling the concept that T-cell suppres- 
sor responses may start in parallel with pro-in- 
flammatory responses, and that the balance between 
competing cytokines dictates the direction and/or 
progression of immunological disorders [40,243]. 
At ensuing of chronicity, when inflammation sub- 
sides and distal pathogenetic phenomena such as 
tissue destruction and fibrosis become prominent, 
Th2 cytokines undergo a second, significant rise lo- 
cally (own observation), as it would be expected on 
the basis of their anti-inflammatory properties. The 
late Th2 rise, however, is also very pronounced in 
regional ymph node and spleen, suggesting that re- 
gional and/or systemic sites significantly contribute 
to the down-regulation of the local inflammatory 
process. 
Whether T-cell activation in regional or systemic 
lymphoid organs plays a role in human RA, in oppo- 
sition or in parallel to synovial activation (see Fig. 3 
for a schematic representation f such working hy- 
potheses), remains matter of speculation. However, 
the fact that splenomegaly and lymphadenopathy ac-
company the most severe forms of RA [22], and that 
total lymphoid irradiation has beneficial effects on 
both human RA and experimental rthritis [244-247], 
may warrant further consideration. In RA patients, of 
note, germinal centers and memory T-cells have been 
identified in inflammatory foci of the subchondral 
bone, close to areas of cartilage destruction [248]; the 
percentage of activated, HLA-DR-positive/CD8- 
positive cells is also increased in the iliac bone 
marrow, well away from the site of inflammation 
[249]; in addition, generation and maturation of 
CD14-positive cells from myeloid progenitors are 
increased [250]. On the basis of these findings, the 
bone marrow appears a potential site for systemic 
T-cell activation. 
4. The contribution of animal models to the under- 
standing of the role of T-cells in arthritis 
The study of several experimental models of arthri- 
tis has greatly supported the view that T-cells are 
essential to the development of arthritis; each model 
contributes to basic aspects of T-cell involvement and 
regulation in arthritis, although none of them can be 
directly compared to human RA [204,251]. More 
recently, the ever increasing availability of geneti- 
cally manipulated animals with ablation or dysregu- 
lated expression of features of T-cell function poten- 
tially relevant to arthritis promises to define the 
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molecular basis of the T-cell involvement (reviewed 
in [252]). 
Classically, the T-cell paradigm funds on the fact 
that experimental rthritides develop in euthymic, but 
not in athymic nude rats [253,254], and that transfer- 
ral of T-cell clones adoptively causes or protects 
against disease ([149,255]; see below). Of great inter- 
est, the phenotypes linked to inducing- or protective 
T-cells cannot always be distinguished from one an- 
other ([149,256]; see below), suggesting that even in 
animals the characterization f disease-causing T-cells 
is far from being completed. 
4.1. Adoptive transfer of disease by T-cells 
Experimental rthritides, including the prevalently 
local antigen-induced arthritis, can be transferred from 
arthritic to naive animals by using thoracic duct, 
spleen or lymph node T-cells (reviewed in [204]), or, 
more specifically, T-cell clones (reviewed in [149]). 
The capacity of disease transfer is contained within 
the CD4-positive T-cell subpopulation (reviewed in 
[118]); in adjuvant arthritis, T-cells employed for 
adoptive transfer espond to the amino acid sequence 
180-188 of the mycobacterial heat shock protein 
contained in the emulsion used to induce arthritis, as 
well as to collagen II, one of the normal constituents 
of articular cartilage, providing thus experimental 
evidence for the concept of cross-reactivity between 
microbial and self-constituents [149]. 
Quantitatively speaking, spleen or lymph node T- 
cells have to be activated in vitro and given at high 
threshold numbers in order to elicit the adoptive 
disease; also, there exists a clear dose-response r la- 
tionship between the number of cells and the severity 
of adoptive arthritis [15]. Below a minimal threshold, 
interestingly, T-cells actually protect animals from 
arthritis, a phenomenon defined as low-dose T-cell 
vaccination [257]. The straightforwardness of the lat- 
ter concept, together with the fact that the exact 
knowledge of arthritogenic epitopes may not be nec- 
essary, renders T-cell vaccination an interesting means 
to silence autoreactive processes [15,111,136,149, 
257]. 
4.2. Adoptive protection against disease 
Transferral of lymph node T-cells isolated from 
animals recovering from adjuvant synovitis renders 
naive rats refractory to subsequent induction of adju- 
vant arthritis (reviewed in [118]). Antigen-specific 
T-cells, in turn, adoptively suppress collagen-induced 
arthritis (reviewed in [3]). Interestingly, not the 
CD8-positive T-cells with presumable suppressor/ 
regulatory functions, but the CD4-positive T-cells 
accused of causing disease can adoptively suppress 
disease [256], implying that CD4-positive T-cells 
contain regulatory as well as disease-inducing sub- 
sets. 
The discovery that immunization with the my- 
cobacterial 65 kD heat shock protein induces resis- 
tance to experimental rthritides [251,258] has led to 
identification of the epitope 256-270 as critical for 
the induction of passive protection (in contrast to the 
pro-arthritogenic epitope 180-188); accordingly, ce/3 
T-cell receptor/CD4-positive T-cell lines specific for 
this sequence counteract the development of arthritis 
[259]. Interestingly, T-cells specific for the 256-270 
epitope of the mycobacterial heat shock protein are 
cross-reactive with the 256-270 sequence of the rat 
60 kD heat shock protein [259], suggesting that 
mimicry between self- and non-self constituents may 
not only be the basis of autoimmunity (as observed 
with the pro-arthritogenic sequence 180-188), but 
also of disease regulation. 
Of note, the presence of adjacent epitopes with 
disease-causing and disease-regulating potential 
within a given protein is revealing an important 
factor in autoimmunity (reviewed in [40]), as recent 
studies on the mechanisms of disease suppression 
generated by oral tolerance also implicate (see below, 
[260,261]). 
4.3. Arthritis in genetically manipulated experimental 
animals 
Evidence in favour of the hypothesis that T-cells 
contribute to very proximal, although not necessarily 
primary, aspects of arthritis derives from mice trans- 
genic for human HLA haplotypes linked to genetic 
RA susceptibility which document that chronic arthri- 
tis and autoreactivity can be generated by such a 
condition [123]; also, animals transgenic for myelin 
basic protein-specific T-cell receptor can develop 
spontaneous allergic myelitis [187]. 
An interesting case is represented by the so called 
MRL lpr/Ipr (i.e., lymphoproliferation gene) ho- 
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mozygous mouse, a model characterized by arthritis, 
encephalitis, humoral autoimmunity, lymphoprolifer- 
ation, and increased levels of retroviral sequences 
[reviewed in 252]. In these mice, abnormalities boil 
down to a single molecular defect, i.e., the presence 
of a retrotransposon in the second intron of the fas 
apoptosis gene, leading to defective xpression of the 
Fas protein, defective rates of apoptosis, and thence 
pathological accumulation of T-cells in lymphoid 
organs. Selective transgenic re-establishment of fas 
expression in T-cells leads to correction of the main 
pathological features of the disorder, including nor- 
malization of cellular and humoral autoimmunity 
[252]. These findings have led to the unifying hypoth- 
esis that retroviral sequences may be a cause, and 
defects in apoptosis a main mechanism for autoim- 
mune diseases [252]. While this hypothesis needs 
appropriate t sting, initial studies on apoptosis in the 
RA SM reveal that apoptotic death regards in fact 
synovial macrophages and fibroblasts more than T- 
cells [262]. 
Quite at the opposite nd of the spectrum, studies 
in homozygous cid. (severe combined immunodefi- 
ciency) beige mice seem to deny that T-cells are 
necessary at all for the development of arthritis. 
These mice, which bear a primary defect of the 
rearrangement of antigen receptor genes in T-cells 
and B-cells, and therefore do not carry functional 
T-cells, develop chronic, erosive arthritis upon im- 
plantation of human rheumatoid synovial tissue or 
purified synovial fibroblasts ([263], reviewed in 
[264]). 
Likewise, infection of scid mice with Borrelia 
burgdorferi, the causative agent of Lyme disease, 
results in erosive arthritis in spite of the lack of 
functional T-cells (reviewed in [265]), emphasizing 
the importance of macrophages in arthritis [235]; 
however, more recent studies uggest that the lack of 
protective T- and B-cells, rather than the lack of 
disease-inducing T-cells, underlies this model [265]. 
5. Anti-T-cell treatments in human and experi- 
mental arthritis 
Treatments with partial or complete selectivity for 
T-cells suppress human or experimental rthritides 
(reviewed in [266]). Along with the characterization 
of very fine functional/phenotypic features of in- 
flammatory T-cells, the strategies in this field have 
evolved from non-selective means to the use of mon- 
oclonal antibodies with very fine specificities for 
selected T-cell surface molecules. 
5.1. Anti-pan T-cell treatments 
Total lymphoid irradiation [244-247], directed at 
radiation-sensitive lymph node T-cells, or drainage of 
the thoracic duct lymph [267], leukapheresis [46], and 
lymphapheresis [268,269], can be considered anti- 
pan-T-cell approaches. Their application in cases of 
RA refractory to conventional treatments leads to 
clinical amelioration; however, technical difficulties 
and severe side-effects limit very much their pro- 
longued use. In addition, at least in the case of 
leukapheresis and anti-CD4 monoclonal antibodies, 
clinical efficacy may result not only from modulation 
of T-cell function but also from dowregulation of 
macrophage activation (reviewed in [235]). 
Monoclonal antibodies directed at surface antigens 
present on virtually all T-cells have proven effective 
in suppressing rat adjuvant arthritis [270], and human 
RA [139,271 ]. The CAMPATH- 1H monoclonal anti- 
body directed at the pan-T-cell CD52 antigen does 
ameliorate human RA [139,271], however clinical 
flares ensue in spite of long-lasting depletion of 
circulating T-cells [ 139]. 
5.2. Anti-rheumatic therapy with partial specificio' 
for T-cells 
Prototypes of pharmacological nti-T-cell treat- 
ment of human RA are cyclosporin A and the FK506 
molecule, which inhibit transcription of IL-2- and 
IL-2-receptor genes (reviewed in [272]), thereby po- 
tentially affecting activation-related T-cell function 
[82,272,273]; as considered in different parts of this 
paper (Table 1, Fig. 2), in RA the minority of IL-2 
receptor-positive/CD4-positive T-c lls could repre- 
sent a subset of recently antigen-activated and/or 
oligoclonally expanded T-cells both locally and sys- 
temically (Table 2; [4,83,92,97,169,178]). Therefore, 
the use of cyclosporin A closely adheres to the 
concept of selective targeting of T-cells most actively 
engaged in autoimmunity. Accordingly, this drug ap- 
pears efficacious in suppressing RA [274], with dis- 
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ease-controlling effects, i.e., long-term counteraction 
of objective signs of joint destruction i  established 
[275-277] and early RA [278]; its use, however, 
remains greatly limited by nephrotoxicity [279]. 
Cyclosporin A has proven effective also in experi- 
mental arthritides [118,280], although suspension of 
treatment is accompanied by immediate and strong 
clinical rebound [118]. Conceivably, while the end 
step of T-cell activation (as shown in Fig. 2) is kept 
under control because the production of IL-2 and/or 
the IL-2 receptor by stimulated T-cells is inhibited, 
the preceding steps of antigen processing and pre- 
sentation remain untouched, creating a condition in 
which autoreactive T-cell engagement can further 
proceed, once cyclosporin A is suspended [118]. 
Selective neutralization f the IL-2 activation path- 
way using monoclonal antibodies against the IL-2 
receptor achieved in turn limited success [240,281, 
282]. More recently, however, an IL-2 diphteria fu- 
sion toxin (DAB486IL-2) targeted to IL-2-receptor- 
positive cells, and conceivably able to selectively 
eliminate IL-2-receptor-positive r cently activated 
T-cells, was effective in suppressing experimental 
arthritis [283] as well as human RA refractory to 
conventional treatment [125,284]. Long-term efficacy 
and safety of this selective approach now remain to 
be determined. 
5.3. Anti-T-cell-receptor monoclonal antibodies 
Interference with variable and constant regions of 
the T-cell receptor has been attempted in several 
models of autoimmunity. Treatment with monoclonal 
antibodies against V/3 gene families, or else immu- 
nization with Vfl chain peptides, did prevent colla- 
gen-induced arthritis [180,181,183,285] as well as 
exper imenta l  al lergic encepha lomye l i t i s  
[185,286,287]. In turn, treatment with antibodies di- 
rected at the constant region of the aft T-cell recep- 
tor suppressed and/or prevented most arthritides 
[288-292], indicating that disease-causing T-cells 
hide within the a/3 T-cell subpopulation. An anti-in- 
flammatory role seems to be ascribed instead to the 
small T6 T-cell population (1-5% of circulating 
T-cells; reviewed in [55]; Fig. 2); treatment with 
monoclonal ntibodies against the T6 T-cell receptor, 
in fact, aggravated joint destruction i both collagen- 
induced and adjuvant arthritis [292,293], in analogy 
to spreading of local damage in other models of 
inflammation upon T6 T-cell depletion (reviewed in 
[292]). 
It emerges thus that o~/3 and T6 T-cells may 
represent functionally antithetical subpopulations, 
with different emporal and spatial domains in the 
course of autoimmunity (reviewed in [292]); these 
features may be optimally exploited for treatment 
strategies. 
5.4. Monoclonal antibodies against CD4-positive T- 
cells 
The converging evidence that CD4-positive T-cells 
play a critical role in the development of arthritis has 
naturally merged in the concept that specific anti-CD4 
treatment is a rational means to treat RA, in analogy 
to experimental rthritis ([118,294,295], and others). 
The CD4 molecule acts as co-receptor during the 
process of antigen recognition (Fig. 2), and contains 
therefore the potential to profoundly affect basic im- 
munological phenomena underlying RA. Indeed, the 
capacity of anti-CD4 monoclonal antibodies to in- 
duce permanent graft acceptance in animal models of 
transplantation is compatible with induction of anti- 
gen-specific tolerance (reviewed in [12]). In animals, 
for example, tolerance (or active suppression) to cer- 
tain antigens can be achieved if these are given under 
the ' protection' of sufficiently high levels of anti-CD4 
monoclonal antibodies [12,296]. If arthritis involves 
recognition of (auto)antigens, 're-programming of the 
immune system' towards re-establishment of proper 
control of natural autoimmunity, for example by us- 
ing anti-CD4 monoclonal antibodies, may thus be- 
come the elective choice for treatment [12]. 
Over the last decade, several reports have been 
published on the use of anti-human-CD4 monoclonal 
antibodies, including murine [50,297-300], chimeric 
[301-304], primatized [305], or fully humanized anti- 
bodies [306]. The general conclusions are thus far 
conflictual [307], stressing the necessity for long-term, 
double blind studies to settle the issue of clinical 
efficacy [307]. Several parameters seem to influence 
the treatment outcome; anergic patients, for example, 
seem to respond better than the rest of the study 
population [50]. Also, while the clinical efficacy does 
not correlate with duration/degree of peripheral T- 
cell depletion, the ability to coat target cells appears 
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to predict clinical benefit [308], suggesting that func- 
tional changes, rather than depletion of target CD4- 
positive T-cells may play an important role; upon 
prolonged in vitro exposure, for example, anti-CD4 
monoclonal antibodies convey inhibitory signals to 
their target cells [309,310]. Also, the CD4 epitope 
against which antibodies are directed may be critical, 
as shown in animal models [311,312] or in in vitro 
experiments [313]. 
5.5. Monoclonal antibodies against CD8-positive T- 
cells 
As summarized in Fig. l, not only CD4-positive 
T-cells, but also CD8-positive T-cells undergo clear 
changes in their frequency in peripheral blood, syn- 
ovial fluid, and SM of RA patients. Also, IL-2-recep- 
tor-positive CD8-positive T-cells undergo biased V/3 
gene usage and/or oligoclonal expansion in periph- 
eral blood and synovial tissue ([ 166,171,314]; Table 
2). Their activation is furthermore indicated by the 
presence of CD8-positive T-cell blasts in transitional 
areas of the inflamed SM [30,189]. Early demonstra- 
tion of the clinical inefficacy of anti-CD8 treatment 
in adjuvant arthritis appeared to exclude any appre- 
ciable influence of this subpopulation [270]; more 
recent studies, however, indicate that a combination 
of anti-CD4- and anti-CD8 monoclonal antibodies 
affects some parameters of adjuvant arthritis in a 
fashion that clearly differs from that of anti-CD4 
monotherapy [315]. More importantly, anti-CD8 
treatment aggravates both clinical and histopathologi- 
cal signs of antigen-induced arthritis [316], consis- 
tently with the hypothesis that activation of CD8- 
positive T-cells in transitional, presumably active ar- 
eas of the RA SM, may in fact represent an attempt 
to down-regulate disease [30]. 
5.6. Blockade of T-cell immigration 
Blockade of T-cell adhesion molecules appears a 
straightforward way of reducing T-cell infiltration in 
synovitis [317]. The therapeutic usefulness of such an 
approach (reviewed in [318]) remains however to be 
elucidated since, at least in chronic RA, T-cell immi- 
gration appears dictated for the most part by sec- 
ondary phenomena nd not by antigen-specificity 
[4,100,101 ]. Studies of T-cell migration in adoptive 
transfer of experimental rthritides confirm that infil- 
tration of pathogenic T-cells in the SM is minute 
[242,319]. 
6. Therapeutic perspectives 
From the several issues considered, it emerges that 
anti-T-cell therapy is a rational and legitimate ap- 
proach for breaking and/or regulating the underlying 
autoimmune process in RA, provided that the primary 
goal is specific targetting of the very minority of 
disease-promoting T-cells, i.e., those that may insti- 
gate flares at each round of the disease. In contrast, 
utilization of non-selective anti-T-cell treatments i
less acceptable for several reasons: 1) the beneficial 
function of naturally occurring disease-regulating T- 
cell subpopulations (CD8-positive and/or CD4-posi- 
tive T-cells of the Th2-type, and/or perhaps y6 
T-cells) may be ablated; 2) a broad anti-inflamma- 
tory/anti-rheumatic approach should be directed at 
cells more directly involved in tissue pathology than 
T-cells, for example macrophages and/or fibroblasts 
[7,235,320,321]; and 3) even within the process of 
antigen recognition underlying autoimmunity (Fig. 
2), T-cells cannot be considered anymore the only 
possible culprit, as antigen-presenting cells (via dis- 
ease-susceptibility genes and/or the second signal 
system), or the cytokine milieu existing at sites in 
which antigen recognition occurs, can largely influ- 
ence autoimmunity [322]. 
Thus, in view of the attempt of targetting very 
specific functions of T-cells in autoimmunity, several 
therapeutical possibilities are under scrutiny, at least 
conceptually. They can be grouped under three main 
kinds: 1) antigen-specific immunotherapy, which 
needs unequivocal identification of disease-causing 
epitopes for a most radical and profitable intervention 
[13,14]; 2) immune deviation, an approach that is 
'satisfied' with changing the microenvironment that 
favours autoimmunity [105,323,324]; and 3) interfer- 
ence at the level of the T-cell receptor. 
6.1. Antigen-specific immunotherapy 
(a) Oral tolerance. This phenomenon is classically 
induced when antigens, otherwise immunogenic, are 
introduced into the organism through the gut (re- 
viewed in [261]). The modem concept of oral toler- 
ance as a prototype of specific immunotherapy is that 
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antigen-specific T-cells, elicited in the lymph nodes 
that drain the gut, acquire the capacity of down-regu- 
lating the immunological response to that particular 
antigen. Depending on the dose of the antigen orally 
administered, antigen-specific CD8-positive suppres- 
sor T-cells, producing the regulatory cytokine TGF-fl, 
or CD4-positive T-helper cells, producing the regula- 
tory Th2 cytokines IL-4 or IL-10, can be generated 
[325]. Both types of T-cells exert a protective role, 
conceivably suppressing pre-existing autoreactive T-
cells [325]. 
Induction of oral tolerance to autoantigenic pro- 
teins has been already devised for therapy 
[261,326,327]. While preclinical trials in experimen- 
tal animals have proven remarkably effective 
[328,329], initial results in human autoimmune dis- 
eases are less convincing. Patients with multiple scle- 
rosis orally treated with myelin basic protein respond 
variably, with some patients experiencing long-term 
remission and others not responding at all [261]. In 
the case of RA, patients orally treated with collagen 
II, that is, an antigen (among several others) only 
suspected to be autoantigenic, also respond variably 
to treatment [326,327]. It is thought that different 
doses [325] or schedules of administration of the 
antigens, as well as the peptide sequence presented to
T-cells in the gut [260], largely influence formation 
of tolerance and thereby the clinical efficacy in hu- 
man diseases. To circumvent these problems, offering 
selected peptides through the nasal mucosa, a route 
which also induces protective CD4-positive T-cells, 
may reveal a precious trategy [330]. 
(b) Altered peptide ligands for the T-cell receptor. 
A very interesting experimental pproach is to modu- 
late T-cell reactivity by using peptides in which the 
anchoring point to the respective T-cell receptor is 
altered by one or a few amino acid exchanges 
[331,332]. Experimental allergic encephalomyelitis 
induced by a peptide of the myelin phospholipid 
protein, for example, can be prevented by administra- 
tion of a peptide ligand altered in one anchor amino 
acid; this treatment elicits protective Th2-cells cross- 
reactive with the inducing peptide, cells that are in 
turn capable of adoptively transferring protection 
[331]. Quite strikingly, administration of a different 
altered peptide ligand reverses established disease not 
only clinically but also histopathologically [332]. 
(c) T-cell vaccination. In experimental models of 
autoimmunity administration f very low numbers of 
T-cell clones specific for the disease-inducing antigen 
leads to 'vaccination', that is, animals become refrac- 
tory to subsequent induction of adoptive disease ven 
with T-cell numbers that usually induce a severe 
form of the disease (reviewed in [15]). In human 
multiple sclerosis, vaccination elicits both Th2-type 
CD4-positive T-cells and CD8-positive T-cells [333], 
thus T-cells with protective or regulatory potential; 
however, there are as yet no complete reports on the 
clinical efficacy of this approach. 
6.2. Immune deviation 
The evergrowing knowledge about cytokine net- 
works offers powerful means to manipulate the mi- 
lieu in which autoimmunity progresses, especially in 
view of the potential of cytokines to influence the 
outcome of antigen recognition [322] and/or to con- 
trol the spreading of autoimmunity o cryptic deter- 
minants [105]. The most obvious possibilities are the 
experimental dministration of antibodies that neu- 
tralize Thl pro-inflammatory c tokines uch as IFN-y 
[334], or, more elegantly, the administration of Th2 
cytokines that exert a regulatory function on Thl 
T-cells [323,324], as well as on activated macrophages 
[335]. Treatment with IL-4, for example, can deviate 
the immune response to a protective one, since in 
vitro, this cytokine is the driving force in eliciting 
Th2 regulatory cytokines [52]. Treatment of experi- 
mental allergic encephalomyelitis with IL-4, accord- 
ingly, does not merely suppress inflammation, but 
up-regulates specific Th2 responses against he au- 
toantigen myelin basic protein [323]. Since, as previ- 
ously mentioned, the cytokine milieu greatly affects 
the induction and propagation of autoimmunity, it is 
possible that, under the influence of IL-4, newly 
forming autoreactive T-cells not yet committed to a 
functional cytokine pathway can be diverted to a Th2 
protective response through production of IL-5 and 
IL-10 instead of IFN-T and IL-2 [324]. On the other 
hand, the ability to generate a shift towards Th2 
immunoregulatory cytokines may be common to other 
treatments, whether or not directed at T-cells, for 
example monoclonal antibodies against he cytokine 
TNF-ol in humans [321], or, in experimental nimals, 
monoclonal antibodies against CD3 ([336]; see Fig. 
2), or else deaggregated gamma globulins [337]. 
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A most recent and fascinating development within 
the concept of immune deviation appears the suppres- 
sion of autoimmunity through manipulation of the 
second signal offered to CD4-positive T-cells by 
antigen-presenting cells in the framework of the 'im- 
munological synapse' (Fig. 2; reviewed in [75]). In 
animal studies, in fact, the second signals B7-1 
(CD80) and B7-2 (CD86) expressed by antigen-pre- 
senting cells seem to favour alternative selection of 
the Thl or the Th2 pathway, respectively, so that 
their neutralization reduces or aggravates experimen- 
tal allergic encephalomyelitis [74]. Success has also 
been reported in organ transplantation following 
treatment with soluble second signal ligand CTLA-4 
[338]. 
6.3. Interference with the T-cell receptor 
more precisely defined. The importance of comple- 
mentary, yet critical, antigen-presenting cells within 
the functional unit forming at antigen recognition is 
also recognized. The considerable body of observa- 
tions gathered in these aspects now awaits preclini- 
cal/clinical testing, in order to understand how well 
given principles apply to the human condition. It may 
also become possible to test whether the main fea- 
tures of RA, including the concomitant engagement 
of immune and mesenchymal cells, the clear alter- 
ation of immune responses (i.e., T- and B-cell activa- 
tion, T-cell oligoclonal expansion, autoreactivity, and 
anergy) do not in fact obey to a unitary etiopatho- 
genetic principle, may it be a molecular defect or a 
viral 'thorn in the foot' [339]. It may not be too 
optimistic to expect major clinical breakthroughs. 
A rational approach to elimination of the effects of 
(auto)antigen recognition is to target specifically ex- 
panded T-cells via monoclonal antibodies directed 
against expanded Va//3 families of the T-cell recep- 
tor (Fig. 2), or, more specifically, with antibodies 
blocking the complementarity determining regions 
within the T-cell receptor ('anti-id antibodies'). How- 
ever, the as yet unclear link between T-cell expansion 
and pathogenesis of RA (Table 2) and the variability 
of the predominant Vc~//3 families and/or T-cell 
clones within individual patients (and even more so 
among different patients; Table 2) make interference 
with the T-cell receptor difficult to apply, if not on a 
single-patient basis. Also, as disease-promoting and 
disease-suppressing T-cell clones may not greatly 
differ in their T-cell receptor usage or surface pheno- 
type [328], this approach may not guarantee the 
expected specificity. 
7. Conclusions 
There has been a tremendous improvement of the 
understanding of basic mechanisms of immunity and 
autoimmunity. The role of T-cells in autoimmunity, 
which may trespass the boundaries of the primary 
organ of pathology (Fig. 3), and the 'plasticity' of 
antigen-driven T-cell responses over time, are now 
8. Addendum 
Recently, the hypothesis that collagen II (C II) is a 
candidate autoantigen i arthritis has been subjected 
to experimental proof, with regard to binding of 
collagen peptides to both human HLA-DR and CD4 
molecules transgenically expressed in mice [360]. 
This analysis has singled out the conserved 261-273 
residues of bovine C II, which, interestingly, overlap 
with the sequence critical to induction of murine 
collagen-induced arthritis. 
Acknowledgements 
We are indebted to Prof. Inga Melchers and Prof. 
G.R. Burmester for discussing the manuscript, and to 
Prof. J.R. Kalden and Prof. K. von der Mark for 
support. Drs. C. Schmidt-Weber and E. Buchner are 
gratefully acknowlegded for cytokine analyses and 
animal experiments. We acknowledge the work of all 
those who could not be cited for reasons of space, 
especially in the seminal fields of characterization f 
the trimolecular complex in antigen recognition, and 
manipulation of T-cells in animal models of arthritis. 
Dr. Kinne and Prof. Emmrich were funded by the 
German Ministry for Research and Technology 
(BMFT; FKZ 01VM9311; FKZ 01VM8702). 
134 R. W. Kinne et al. / Biochimica et Biophysica Acta 1360 (1997) 109-141 
References 
[1] Janossy, G., Duke, O., Poulter, L.W., Panayi, G.S., Bofill, 
M. and Goldstein, G. (1981) Lancet ii, 839-842. 
[2] Harris, E.D. Jr. (1990) N. Engl. J. Med. 322, 1277-1289. 
[3] Fox, D.A., Millard, J.A., Kan, L., Zeldes, W.S., Davis, W., 
Higgs, J., Emmrich, F. and Kinne, R.W. (1990) J. Clin. 
Invest. 86, 1124-1136. 
[4] Panayi, G.S., Lanchbury, J.S. and Kingsley, G.H. (1992) 
Arthritis Rheum. 35, 729-735. 
[5] Goronzy, J.J. and Weyand, C.M. (1993) Curr. Opin. 
Rheumatol. 5, 169-177. 
[6] Smolen, J.S., Tohidast-Akrad, M., Gal, A., Kunaver, M., 
Eberl, G., Zenz, P., Falus, A. and Steiner, G. (1996) Scand. 
J. Rheumatol. 25, 1-4. 
[7] Firestein, G.S. and Zvaifler, N.J. (1990) Arthritis Rheum. 
33, 768-773. 
[8] Firestein, G,S. and Zvaifler, N.J. (1992) in Inflammation: 
Basic Principles and Clinical Correlates, 2nd Ed. (Gallin, 
J.I., Goldstein, I.M. and Snyderman, R., eds), pp. 959-975, 
Raven Press. 
[9] Lee, S.K., Bridges, L.S. Jr., Koopman, W.J. and Schroeder, 
H.W. (1992) Arthritis Rheum. 35, 905-913. 
[10] Olee, T., Lu, E.W., Huang, D.-F., Soto-Gil, R.W., Deftos, 
M., Kozin, F., Carson, D.A. and Chen, P.P. (1992) J. Exp. 
Med. 175, 831-842. 
[11] Struyk, L., Hawes, G.E., Dolhain, R.J.E.M., van Scherpen- 
zeel, A., Godthelp, B., Breedveld, F.C. and van den Elsen, 
P.J. (1994) Int. Immunol. 6, 897-907. 
[12] Cobbold, S.P., Qin, S., Leong, L.Y,W., Martin, G. and 
Waldmann, H. (1992) Immunol. Rev. 129, 165-201. 
[13] Tisch, R. and McDevitt, H. (1994) Proc. Natl. Acad. Sci. 
USA 91,437-438. 
[14] Klareskog, L., Rtinnelid, J. and Holm, G. (1995) J. Intern. 
Med. 238, 191-206. 
[15] Segel, L.A., J~iger, E., Elias, D. and Cohen, I.R. (1995) 
Immunol. Today 16, 80-84. 
[16] Stastny, P. (1978) N. Engl. J. Med. 298, 869-871. 
[17] Nepom, G.T. and Erlich, H. (1991) Annu. Rev. Immunol. 
9, 493-525. 
[18] Vaughan, J.H., Kouri, T., Petersen, J., Roudier, J. and 
Rhodes, G.H. (1988) Scand. J. Rheumatol., 74(S), 19-28. 
[19] Harris, E.D. Jr. (1993) in Textbook of Rheumatology, 4th 
Ed., (Kelley, W.N., Harris, E.D. Jr., Ruddy, S. and Sledge, 
C.B., eds.) Saunders. 
[20] Gardner, D.L. (1994) J. Anat. 184, 465-476. 
[21] Smiley, J.D., Sachs, C. and Ziff, M. (1968) J. Clin. Invest. 
47, 624-632. 
[22] Pinals, R. (1985) in Textbook of Rheumatology (Kelley, 
W.N., Harris, E.D. Jr., Ruddy, S., Sledge, C.B., eds.), 2nd 
ed., pp. 950-955, Saunders. 
[23] Pincus, T. and Callahan, F. (1993) Rheum. Dis. Clin. N. 
Amer. 19, 123-151. 
[24] Wolfe, F., Mitchell, D.M., Sibley, J.T., Fries, J.F., Bloch, 
B.A., Williams, C.A., Spitz, P.W., Haga, M., Kleinheksel, 
S.M. and Cathey, M.A. (1994) Arthritis Rheum. 37, 481- 
494. 
[25] Edwards, J.C.W. (1982) Immunobiology 161,227-231. 
[26] Van Boxel, J.A. and Paget, S.A. (1975) N. Engl. J. Med. 
293, 517-520. 
[27] Bankhurst, A.D., Husby, G. and Williams, R.C. (1976) 
Arthritis Rheum. 19, 555-562. 
[28] Burmester, G.R., Dimitriu-Bona, A., Waters, S.L and 
Winchester, R.J. (1983) Scand. J. Rheumatol. 17, 69-82. 
[29] Burmester, G.R., Jahn, B., Gramatzi, M., Zacher, J. and 
Kalden, J.R. (1984) J. Immunol. 133, 1230-1234. 
[30] Kurosaka, M. and Ziff, M. (1983) J. Exp. Med. 158, 
1191-1210. 
[31] Duke, O., Panayi, G.S., Janossy, G. and Poulter, L.W. 
(1982) Clin. Exp. Immunol. 49, 22-30. 
[32] Pitzalis, C., Kingsley, G.H., Murphy, J. and Panayi, G.S. 
(1987) Clin. Immunol. Immunopathol. 45, 252-258. 
[33] Lasky, H.P., Bauer, K. and Pope, R.M. (1988) Arthritis 
Rheum. 31, 52-59. 
[34] Cush, J.J. and Lipksy, P.E. (1988) Arthritis Rheum. 31, 
1230-1238. 
[35] Fox, R.I., Fong, S., Sabharwal, N., Carstens, S.A., Kung, 
P.C. and Vaughan, J.H. (1982) J. Immunol. 128, 351-354. 
[36] Veys, E.M., Hermanns, P., Verbrugghen, G., Schindler, J. 
and Goldstein, G. (1982) J. Rheumatol. 9, 821-826. 
[37] Verwilghen, J., Vertessen, S., Stevens, E.A.M., Dequeker, 
J. and Ceuppens, J.L. (1990) J. Clin. Immunol. 10, 90-98. 
[38] Haraoui, B., Wilder, R.L., Malone, D.G., Allen, J., Katona, 
I.M. and Wahl, S.M. (1984) J. Immunol. 133, 697-701. 
[39] Rooney, M., Whelan, A., Feighery, C. and Bresnihan, B. 
(1989) Arthritis Rheum. 32, 361-369. 
[40] Mitchison, A. (1992)Annu. Rev. Immunot. 10, 1-12. 
[41] Zvaifler, N. (1973) Immunology 16, 265-336. 
[42] Ziff, M. (1974) Arthritis Rheum. 17, 313-319. 
[43] Berek, C. (1992) Immunol. Rev. 126, 5-19. 
[44] Schr~Sder, A.E., Greiner, A., Seyfert, C. and Berek, C. 
(1996) Proc. Natl. Acad. Sci. USA 93, 221-225. 
[45] Silverman, A.H., Johnson, J.S., Vaughan, J.H. and 
McGlamory, J.C. (1976) Arthritis Rheum. 19, 509-5t5. 
[46] Wahl, S.M., Wilder, R.L., Katona, I.M., Wahl, L.M., 
Allen, J.B., Scher, I. and Decker, J.L. (1983) Arthritis 
Rheum. 26, 1076-1084. 
[47] Combe, B., Pope, R.M., Fishbach, M., Darnell, B., Baron, 
S. and Talal, N. (1985) Clin. Exp. lmmunol. 59, 520-528. 
[48] Emery, P., Wood, N., Gentry, K.C., Stockman, A., Mackay, 
I.R. and Bernard, O. (1988) Arthritis Rheum. 31, 1176- 
1181. 
[49] Emery, P., Panayi, G.S. and Nouri, A.M.E. (1984) Clin. 
Exp. Immunol. 57, 123-129. 
[50] Horneff, G., Burmester, G.R., Emmrich, F. and Kalden, 
J.R. (1991) Arthritis Rheum. 34, 129-140. 
[51] Burmester, G.R. (1991)J. Rheumatol. 18, 1443-1447. 
[52] Paul, W.E. and Seder, R.A. (1994) Cell 76, 241-251. 
R. W. Kinne et al. ,/Biochimica et Biophysica Acta 1360 (1997) 109-141 135 
[53] Von Boehmer, H. (1994) Cell 76, 219-228. 
[54] Marrack, P. and Kappler, J. (1987) Science 238, 1073- 
1079. 
[55] Haas, W., Pereira, P. and Tonegawa, S. (1993) Annu. Rev. 
Immunol. 11,637-668. 
[56] Matis, L.A. (1990) Annu. Rev. Immunol. 8, 65-82. 
[57] Padovam E., Casorati, G., Dellabona, P., Meyer, S., Brock- 
haus, M. and Lanzavecchia, A. (1993) Science 262, 325- 
329. 
[58] Janeway, C.A. (1992)Annu. Rev. Immunol. 10, 645-674. 
[59] Unanue, E.R. and Allen, P.M. (1987) Science 236, 551- 
557. 
[60] Chien, Y.-H. and Davis, M.M. (1993) Immunol. Today 
14, 597-602. 
[61] Steinman, R.M. and Swanson, J. (1995) J. Exp. Med. 182, 
283-288. 
[62] Ron, Y. and Sprent, J. (1987)J. Immunol. 138, 2848-2856. 
[63] Boots, A.M.H., Wimmers-Bertens, A.J.M.M. and Rijn- 
ders, A.W.M. (1994)Immunology 82, 268-274. 
[64] Barnaba, V., Watts, C., De Boer, M., Lane, P. and Lanza- 
vecchia, A. (1994)Eur. J. Immunol. 24, 71-75. 
[65] St. Louis, J.M., Pasick, J.M., Stein, C., Freeman, D., 
Singh, B., Dale, S. and Strejan, G.H. (1994) Cell. Im- 
munol. 156, 36-53. 
[66] Emmrich, F. (1988) Immunol. Today 9, 296-300. 
[67] Weaver, C.T. and Unanue, E.R. (1990) Immunol. Today 
11, 49-55. 
[68] Bonnefoy-Berard, N., Bernard, V., Morel, P., Hmama, Z., 
Verrier, B., Mandrand, B., Vincent, C. and Revillard, J.P. 
(1992) Develop. Biol. Standard 77, 41-48. 
[69] Bretscher, P.A. (1992) Immunol. Today 13, 74-76. 
[70] Schwartz, R.H. (1992) Cell 71, 1065-1068. 
[71] Mondino, A. and Jenkins, M.K. (1994) J. Leukoc. Biol. 55, 
805-815. 
[72] Azuma, M., Cayabyab, M., Buck, D., Phillips, J.H. and 
Lanier, L.L. (1992) J. Exp. Med. 175, 353-360. 
[73] Zadikian, C. and Emmrich, F. (1989) Proceedings of 7th 
International Congress of Immunology, Berlin, Germany. 
[74] Kuchroo, V.K., Prabhu Das, M., Brown, J.A., Ranger, 
A.M., Zamvil, S.S., Sobel, R.A., Weiner, H.L., Nabavi, N. 
and Glimcher, L.H. (1995) Cell 80, 707-718. 
[75] Harlan, D.M., Abe, R., Lee, K.P. and June, C.H. (1995) 
Clin. Immunol. Immunopathol. 75, 99-111. 
[76] Verwilghen, J., Corrigall, V., Pope, R.M., Rodrigues, R. 
and Panayi, G.S. (1993) Immunology 80, 96-102. 
[77] Verwilghen, J., Lovis, R., De Boer, M., Linsley, P.S., 
Haines, G.K., Koch, A.E. and Pope, R.M. (1994) J. Im- 
munol. 153, 1378-1385. 
[78] Liu, M.F., Kohsaka, H., Sakurai, H., Azuma, M., Oku- 
mura, K., Saito, I. and Miyasaka, N. (1996) Arthritis 
Rheum. 39, 110-114. 
[79] Allison, J.P. and Krnmmel, M.F. (1995) Science 270, 
932-933. 
[80] Thomas, R. and Lipsky, P. (1995) Arthritis Rheum. 38, 
1863-1864. 
[81] Ranheim, E.A. and Kipps, T.J. (1995) Arthritis Rheum. 38. 
1864-1865. 
[82] Smith, K.A. (1988) Science 240, 1169-1176. 
[83] Iannone, F., Corrigall, V.M., Kingsley, G.H. and Panayi, 
G.S. (1994) Eur. J. Immunol. 24, 2706-2713. 
[84] Testi, R., D'Ambrosio, D., De Maria, R. and Santoni, A. 
(1994) Immunol. Today 15, 479-483. 
[85] Ko, H., Fu, S.M., Winchester, R.J., Yu, D.T.Y. and Kunkel, 
H.G. (1979) J. Exp. Med. 150, 246-255. 
[86] Blackman, M., Kappler, J. and Marrack, P. (1990) Science 
248, 1335-1341. 
[87] Akbar, A.N., Terry, L., Timms, A., Beverley, P.C. and 
Janossy, G.J. (1988) J. Immunol. 140, 2171-2178. 
[88] Birkenland, M.L., Johnson, P., Trowbridge, I.S. and Pure, 
E. (1989) Proc. Natl. Acad. Sci. USA 86, 6734-6738. 
[89] Beverley, P.C.L. (1990) Immunol. Today 11,203-205. 
[90] Akbar, A.N., Salmon, M. and Janossy, G. (1991) Immunol. 
Today 12, 184-188. 
[91] Mackay, C.R. (1991) Immunol. Today 12, 189-192. 
[92] Cush, J.J., Pietschmann, P., Oppenheimer-Marks, N. and 
Lipsky, P.E. (1992) Arthritis Rheum. 35, 1434-1444. 
[93] Picker, L.J. and Butcher, E.C. (1992) Annu. Rev. Im- 
munol. 10, 561-591. 
[94] Masuyama, J.-I., Berman, J.S., Cruikshank, W.W., Mori- 
moto, C. and Center, M. (1992) J. Immunol. 148, 1367- 
1374. 
[95] Pietschmann, P., Cush, J.J., Lipsky, P.E. and Oppen- 
heimer-Marks, N. (1992)J. Immunol. 149, 1170-1178. 
[96] Brezinschek, R.I., Lipsky, P.E., Galea, P., Vita, R. and 
Oppenheimer-Marks, N. (1995) J. Immunol. 154, 3062- 
3077. 
[97] Pitzalis, C., Kingsley, G.H., Lanchbury, J.S., Murphy, J. 
and Panayi, G.S. (1987) J. Rheumatol. 14, 662-666. 
[98] Springer, T.A. (1994) Cell 76, 301-314. 
[99] Shimizu, Y., Shaw, S., Graber, N., Gopal, V.T., Horghan, 
K.J., Van Seventer, G.A. and Newman, W. (1991) Nature 
349, 799-802. 
[100] Postigo, A.A., Garcia-Vicuna, R., Diaz-Gonzales, F., Ar- 
royo, A.G., De Landazuri, M.O., Chi-Rosso, G., Lobb, 
R.R., Laflbn, A. and Sanchez-Madrid, F. (1992) J. Clin. 
Invest. 89, 1445-1452. 
[101] Ziff. M. (1991) Arthritis Rheum. 34, 1345-1352. 
[102] Sercaz, E.E., Lehmann, P.V., Ametani, A., Benichou, G., 
Miller, A. and Moudgil, K. (1993) Annu. Rev. Immunol. 
11,729-766. 
[103] Lehmann, P.V., Forsthuber, T., Miller, A. and Sercaz, E.E. 
(1992) Nature 358, 155-157. 
[104] Kaufman, D.L., Clare-Salzler, M., Tian, J., Forsthuber, T., 
Ting, G.S.P., Robinson, P., Atkinson, M.A., Sercaz, E.E., 
Tobin, A.J., and Lehmann, P.V. (1993) Nature 366, 69-72. 
[105] Elson, C.J., Barker, R.N., Thompson, S.J. and Williams, 
N.A. (1995) Immunol. Today 16, 71-76. 
[106] Lanzavecchia, A. (1995) J. Exp. Med. 181, 1945-1948. 
[107] Vidard, L., Rock, K.L. and Benacerraf, B. (1992) J. lm- 
munol. 149, 1905-1911. 
136 R.W. Kinne et al. / Biochimica et Biophysica Acta 1360 (1997) 109-141 
[1081 
[109] 
[1101 
[111] 
[112] 
[113] 
[114] 
[115] 
[116] 
[1171 
[118] 
[119] 
[120] 
[121] 
[122] 
[1231 
[124] 
[125] 
[1261 
[127] 
[1281 
[129] 
[130] 
[1311 
[1321 
[1331 
Schild, H., R~Stzschke, O., Kalbacher, H. and Rammensee, 
H.-G. (1990) Science 247, 1587-1589. 
Mamula, M.J. (1993) J. Exp. Med. 177, 567-571. 
Matzinger, P. (1994) Annu. Rev. Immunol. 12, 991-1045. 
Breedveld, F.C., Struyk, L., Van Laar, J.M., Miltenburg, 
A.M.M., De Vries, R.R.P. and Van den Elsen, P.J. (1995) 
Immunol. Rev. 144, 5-16. 
Fowell, D. and Mason, D. (1993) J. Exp. Med. 177, 
627-636. 
Nossal, G.J.V. (1994) Cell 76, 229-239. 
Beverly, B., Kang, S.-M., Lenardo, M.J. and Schwartz, 
R.H. (1992) Int. Immunol. 4, 661-671. 
Ohashi, P.S., Oeheu, S., Biirki, K., Pircher, H., Ohashi, 
C.T., Odermatt, B., Malissen, B., Zinkernagel, R.M. and 
Hengartner, H. (1991)Cell 65, 305-317. 
Rticken, M., Urban, J.F. and Shevach, E.M. (1992) Nature 
359, 79-82. 
Nanishi, F. and Battisto, J.R. (1991) Arthritis Rheum. 34, 
180-186. 
Billingham, M.E.J. (1994) in Immunopharmacology of 
Joints and Connective Tissue, pp. 65-86, Academic Press. 
Winchester, J., Dwyer, E. and Rose, S. (1992) in Genetic 
Factors (Nepom, G., ed.) pp. 761-783, Barton Dudlick. 
Wordsworth, P. (1992) Curr. Opin. Immunol. 4, 766-769. 
Gregersen, P.I., Silver, J. and Winchester, R.J. (1987) 
Arthritis Rheum. 30, 1205-1213. 
Weyand, C.M., McCarthy, T.G. and Goronzy, J.J. (1995) 
J. Clin. Invest. 95, 2120-2126. 
Nabozny, G.H., Baisch, J.M., Cheng, S., Cosgrove, D., 
Griffiths, M.M., Luthra, H.S. and David, C.S. (1996) J. 
Exp. Med. 183, 27-37. 
Evans, T.I., Han, J., Singh, R. and Moxley, G. (1995) 
Arthritis Rheum. 38, 1754-1761. 
Moreland, L.W., Sewell, L.K., Trentham, D.E., Bucy, 
P.R., Sullivan, W.F., Schrohenloher, R.E., Shmerling, R.H., 
Parker, K.C., Swartz, W.G., Woodworth, T.G. and Koop- 
man, W.J. (1995) Arthritis Rheum. 38, 1177-1186. 
Zanelli, E., Gonzalez-Gay, M.A. and David, C.S. (1995) 
Immunol. Today 16, 274-278. 
Ito, K., Bian, H-J., Molina, M., Jihong, H., Magram, J,. 
Saar, E., Belunis, C., Bolin, D.R., Arceo, R., Campbell, R., 
Falciona, F., Vidovic, D., Hammer, J and Nagy, Z. (1996) 
J. Exp. Med. 183, 2635-2644. 
Rammensee, H.-G. (1995) Curt. Opin. Immunol. 7, 85-96. 
Wucherpfennig, J.W. and Strominger, J.L. (1995) J. Exp. 
Med. 181, 1597-1601. 
Germain, R.N. (1994) Cell 76, 287-299. 
Hammer, J., Gallazzi, F., Bono, E., Karr, R.W., Guenot, J., 
Valsasnini, P., Nagy, Z.A. and Sinigaglia, F. (1995) J. Exp. 
Med. 181, 1847-1855. 
Verreck, F.A.W., Elferink, D., Vermeulen, C.J., Amons, 
R., Breedveld, F.C., de Vries, R.R.P. and Koning, F. 
(1995) Tissue Antigens 45, 270-275. 
Birkenfeld, P., Haratz, N., Klein, G. and Sulitzeanu, D. 
(1990) Clin. Immunol. Immunopathol. 54, 14-25. 
[134] Allegretta, M., Nicklas, J.A., Subramaniam, S. and Alber- 
tini, R.J. (1990) Science 247, 718-721. 
[135] Oksenberg, J.R., Panzara, M.A., Begovich, A., Mitchell, 
D., Erlich, H.E., Murray, R.S., Shimonkevitz, R., Sherrit, 
M., Rotbard, J., Bernard, C.C.A. and Steinman, L. (1993) 
Nature 362, 68-70. 
[136] Zhang, J., Markovic-Plese, S., Lacet, B., Raus, J., Weiner, 
H.L. and Hailer, D.A. (1994) J. Exp, Med. 179, 973-984. 
[137] Wucherpfennig, J.W. and Strominger, J.L. (1995) Cell 80, 
695-705. 
[138] Yamamoto, K., Sakoda, H., Nakajima, T., Kato, T., Okubo, 
M., Dohi, M., Mizushima, Y., Ito, K. and Nishioka, K. 
(1992) Int. Immunol. 4, 1219-1223. 
[139] Jendro, M.C., Ganten, T., Matteson, E.L., Weyand, C.M. 
and Goronzy, J.J. (1995) Arthritis Rheum. 38, 1242-1251. 
[140] Ikeda, Y., Masuko, K., Nakai, Y., Kato, T., Hasanuma, T., 
Yoshino, S.-I., Mizushima, Y., Nishioka, K. and Ya- 
mamoto, K. (1996) Arthritis Rheum. 39, 446-453. 
[141] Schmidt, D., Goronzy, J.J. and Weyand, C.M. (1996) J. 
Clin. Invest. 97, 2027-2037. 
[142] Waase, I., Kayser, C., Carlson, P.J., Goronzy, J.J. and 
Weyand, C.M. (1996) Arthritis Rheum. 39, 904-913. 
[143] Trentham, D.E., Townes, A.S., Kang, A.H. and David, J.R. 
(1978) J. Clin. Invest. 61, 89-96. 
[144] Trentham, D.E., Dynesius, R.A., Rocklin, R.E. and David, 
J.R. (1978) N. Engl. J. Med. 299, 327-332. 
[145] Londei, M., Savill, C.M., Verhoef, A., Brennan, F., Leech, 
Z.A., Duance, V., Maini, R.N. and Feldman, M. (1989) 
Proc. Natl. Acad. Sci. USA 86, 636-640. 
[146] Glant, T., Csongor, J. and Sziics, T. (1980) Scand. J. 
Immunol. 11,241-252. 
[147] Yan, T., Burkhardt, H., Ritter, T., BriSker, B.M., Mann, 
K.H., Bertling, W.M., Von der Mark, K. and Emmrich, F. 
(1992) Eur. J. Immunol. 22, 51-56. 
[148] Van Schooten, W.C.A., Devereux, D., Ho, C.H., Quan, J., 
Aguilar, B.A. and Rust, C.J.J. (1994) Eur. J. Immunol. 24, 
93-98. 
[149] Van Eden, W. (1991) Immunol. Rev. 12l, 5-28. 
[150] Holoshitz, J., Klajman, A., Drucker, I., Lapidot, Z., Yaret- 
zky, A., Van Eden, W. and Cohen, I.R. (1986) Lancet 
ii,305-309. 
[151] Res, P.C.M., Breedveld, F.C., Van Embden, J.D.A., Schaar, 
C.G., Van Eden, W., Cohen, I.R. and De Vries, R.R.P. 
(1988) Lancet ii, 478-480. 
[152] De Graeff-Meeder, E.R., Van der Zee, R., Rijkers, G.T., 
Schuurman, H.-J., Kuis, W., Bijlsma, J.W.J., Zegers, 
B.J.M. and Van Eden, W. (1991) Lancet 337, 1368-1372. 
[153] Quayle, A.J., Wilson, K.B., Li, S.G., Kjeldsen-Kragh, J., 
Oftung, F., Shimick, T., Sioud, M., Forre, O., Capra, J.D. 
and Natvig, J.B, (1992) Eur. J. Immunol. 22, 1315-1322. 
[154] Burmester, G.R., Altstidl, U., Kalden, J.R. and Emmrich, 
F. (1991) J. Rheumatol. 18, 171-176. 
[155] Paliard, X., West, S.G., Lafferty, J.A., Clemens, J.R., 
Kappler, J.W., Marrack, P. and Kotzin, B.L. (1991) Sci- 
ence 253, 325-329. 
R. W. Kinne et al. / Biochimica et Biophysica Acta 1360 (1997) 109-141 137 
[156] 
[1571 
[158] 
[1591 
[160] 
[161] 
[162] 
[163] 
[1641 
[165] 
[166] 
[167] 
[168] 
[169] 
[170] 
[171] 
[172] 
[173] 
[174] 
[175] 
[176] 
Uematsu, Y., Wege, H., Straus, A., Ott, M., Bannwarth, 
W., Lanchbury, J., Panayi, G.S. and Steinmetz, M. (1991) 
Proc. Acad. Sci. USA 88, 8534-8538. 
Howell, M.D., Diveley, J.P., Lundeen, K.A., Esty, A., 
Winters, S.T., Carlo, D.J. and Brostoff, S.W. (1991) Proc. 
Natl. Acad. Sci. USA 88, 10921-10925. 
Pluschke, G., Ricken, G., Taube, H., Kroninger, S., Melch- 
ers, I., Peter, H.H., Eichmann, K. and Krawinkel, U. 
(1991) Eur. J. Immunol. 21, 2749-2754. 
Sioud, M., Kjeldsen-Kragh, J., Quayle, A., Wiker, H.G., 
Sorskaar, D., Natvig, J.B. and Forre, O. (1991) Scand. J. 
Immunol. 34, 803-812. 
Sottini, A., lmberti, L., Gorla, R., Cattaneo, R. and Primi, 
D. (1991) Eur. J. Immunol. 21,461-466. 
Bucht, A., Oksenberg, J.R., Lindblad, S., Gr~3nberg, A., 
Steinman, L. and Klareskog, L. (1992) Scand. J. Immunol. 
35, 159-165. 
Krawinkel, U. and Pluschke, G. (1992) Immunobiol. 185, 
483-491. 
Lunardi, C., Marguerie, C. and So, A.K. (1992) Clin. Exp. 
Immunol. 90, 440-446. 
Williams, W.V., Fang, Q., Demarco, D., VonFeldt, J., 
Zurier, R.B. and Weiner, D.B. (1992) J. Clin. Invest. 90, 
326-333. 
BrSker, B.M., Korth~iuer, U., Heppt, P., Weseloh, R., de la 
Camp, R., Kroczek, R.A. and Emmrich, E. (1993) Arthritis 
Rheum. 36, 1234-1243. 
DerSimonian, H., Sugita, M., Glass, D.N., Maier, A.L., 
Weinblatt, M.E., Reme, T. and Brenner, M.B. (1993) J. 
Exp. Med. 177, 1623-1631. 
Jenkins, R.N., Nikaein, A., Zimmermann, A., Meek, K. 
and Lipsky, P.E. (1993) J. Clin. Invest. 92, 2688-2701. 
Maruyama, T., Saito, I., Miyake, S., Hashimoto, H., Sato, 
K., Yagita, H., Okumura, K. and Miyasaka, N. (1993) Eur. 
J. Immunol. 23, 2059-2065. 
Goronzy, J.J., Bartz-Bazzanella, P. Hu, W., Jendro, M.C., 
Walser-Kuntz, D.R. and Weyand, C.M. (1994) J. Clin. 
Invest. 94, 2068-2076. 
Li, Y., Sun, G.-R., Tumang, J.R., Crow, M.K. and Fried- 
man, S,M. (1994) J. Clin. Invest. 94, 2525-2531. 
Zagon, G., Tumang, J.R., Li, Y., Friedman, S.M. and 
Crow, M.K. (1994) Arthritis Rheum. 37, 1431-1440. 
Fischer, D.-C., Opalka, B., Hoffmann, A., Mayr, W. and 
Haubeck, H.-D. (1996) Arthritis Rheum. 39, 452-462. 
Stamenkovic, I., Stegagno, M., Wright, K.A., Amento, 
E.P., Colvin, R.B., Duquesnoy, J. and Kurnick, J.T. (1988) 
Proc. Natl. Acad. Sci. USA 85, 1179-1183. 
Chatila, M.K., Pandolfi, F., Stamenkovic, I. Kurnick, J.T. 
(1990) Human Immunol. 28, 252-257. 
Miltenburg, A.M.M., Van Laar, J.M., Daha, M.R., De 
Vries, R.R.P., Van Den Elsen, P.J. and Breedveld, F.C. 
(1990) Scand. J. Immunol. 31, 121-125. 
Korth~iuer, U., Hennerkes, B., Menninger, H., Mages, 
H.W., Zacher, J., Potocnik, A.J., Emmrich, F. and Kroczek, 
R.A. (1992) Scand. J. Immunol. 36, 855-863. 
[177] Cantagrel, A., Alam, A., Coppin, H.L., Mazieres, B. and 
De Preval, C. (1993) Clin. Exp. Immunol. 91, 83-89. 
[178] Cooper, S.M., Dier, D.L., Roessner, K.D., Budd, R.C., 
Nicklas, J.A. (1991) Arthritis Rheum. 34, 537-546. 
[179] Alam, A., Lambert, N., Lulr, J., Coppin, H., Mazieres, B., 
de Preval, C. and Cantagrel, A. (1996) J. lmmunol. 156. 
3480-3485. 
[180] Banerjee, S.J., Haqqi, T.M., Luthra, H.S., Stuart, J.M. and 
David, C.S. (1988) J. Exp. Med. 167, 832-839. 
[181] Chiocchia, G., Boissier, M.-C. and Fournier, C. (1991) 
Eur. J. Immunol. 21, 2899-2905, 
[182] Haqqi, T.M., Anderson, G.D., Banerjee, S. and David, C.S. 
(1992) Proc. Natl. Acad. Sci. USA 89, 1253-1255. 
[183] Osman, G.E., Toda, M., Kanagawa, O. and Hood, L.E. 
(1993) J. Exp. Med. 177, 387-395. 
[184] Holmdahl, R., Vingsbo, C., Hedrich, H., Karlsson, M.. 
Kvick, C., Goldschmidt, T.J. and Gustafsson, K. (1992) 
Eur. J. Immunol. 22, 419-424. 
[185] Wucherpfennig, J.W., Ota, K., Endo, N., Seidman, J.G.. 
Rosenzweig, A., Weiner, H.L. and Hailer, D.A. (1990) 
Science 248, 1016-1019. 
[186] Burns, F.R., Li, X., Shen, N., Offner, H., Chou, Y.K., 
Vanderbark, A.A. and Heber-Katz, E. (1989) J. Exp. Med. 
169, 27-39. 
[187] Goverman, J., Woods, A., Larson, L., Weiner, L.P., Hood, 
L. and Zaller, D.M, (1993) Cell 72, 551-560. 
[188] Mohr, W., Beneke, G. and Mohing, W. (1975) Ann. 
Rheum. Dis. 34, 219-224. 
[189] Nyk~inen, P., Bergroth, V., Raunio, P., NordstrSm, D. and 
Konttinen, Y.T. (1986)Rheumatol. Int. 6, 269-271. 
[190] Lalor, P.A., Mapp, P.I., Hall, P.A. and Revell, P.A. (1987) 
Rheumatol. Int. 7, 183-186. 
[191] Zwillich, S.M., Weiner, D.B. and Williams, W.V. (1994) 
Immunol. Res. 13, 29-41. 
[192] Trepel, F. (1974) Klin. Wschr. 52, 511-515. 
[193] Burmester, G.R., Daser, A., Kamradt, T., Krause, A., 
Mitchison, A.N., Sieper, J. and Wolf, N. (1995) Annu. 
Rev. Immunol. 13, 229-250. 
[194] Torisu, M., Miyahara, T., Shinohara, N., Ohsato, K. and 
Sonozaki, H. (1978) Cancer Immunol. Immunother. 5, 
77-83. 
[195] Fox, R.I., Sportsman, R., Rhodes, G., Lulea, J., Plarson, G. 
and Vaughan, J.H. (1986) J. Clin. Invest. 77, 1539-1547. 
[196] Wilder, R.L. (1994)Curt. Opin. Rheumatol. 6, 295-298. 
[197] Naides, S.J. (1995) Curr. Opin. Rheumatol. 7, 337-342. 
[198] Sato, K., Maruyama, I., Maruyama, Y., Kitajima, I., Naka- 
jima, Y., Higaki, M., Yamamoto, K., Miyasaka, N., Os- 
ame, M. and Nishioka, K. (1991) Arthritis Rheum. 34, 
714-721. 
[199] Iwakura, Y., Tosu, M. and Yoshida, E. (1991) Science 
253, 1026-1028. 
138 R. W. Kinne et al. / Biochimica et Biophysica Acta 1360 (1997) 109-141 
[2oo] 
[2011 
[2021 
[203] 
[2041 
[205] 
Stransky, G., Vernon, J., Aicher, W.K., Moreland, L.W., 
Gay R.E. and Gay, S. (1993) Br. J. Rheumatol. 32, 1044- 
1048. 
Di Giovine, F.S., Bailly, S., Bootman, J., Almond, N. and 
Duff, G.W. (1994) Arthritis Rheum. 37, 349-358. 
Hasunuma, T., Nakajima, T., Aono, H., Sato, K., Matsub- 
ara, T., Yamamoto, K. and Nishioka, K. (1994) Clin. 
Immunol. Immunopathol. 72, 90-97. 
Kinne, R.W., Palombo-Kinne, E. and Emmrich, F. (1995) 
Ann. Rheum. Dis. 54, 501-504. 
Greenwald, R.A. and Diamond, H.S. (1988) CRC Hand- 
book of Animal Models for the Rheumatic Diseases. Vol 
I., CRC Press. 
Cole, B.C., Washburn, L.R. and Taylor-Robinson, D. 
(1985) in. The Mycoplasmas. IV. (Razin, S. and Barile, 
M.F., eds) Academic Press. 
[206] Zinkernagel, R.M., Cooper, S., Chambers, J., Lazzarini, 
R.A., Hengartner, H. and Arnheiter, H. (1990)Nature 345, 
68-71. 
[207] Oldstone, M.B.A., Neremberg, M., Southern, P., Price, J. 
and Lewicki, H. (1991) Cell 65, 319-331. 
[208] Oldstone, M.B.A. (1987) Cell 50, 819-820. 
[209] Haftel, H.M., Chang, Y., Hinderer, R., Hanash, A.M. and 
Holoshitz, J. (1994)J. Clin. Invest. 94, 1365-1372. 
[210] Roudier, J., Petersen, J., Rhodes, G.H., Luka, J. and Car- 
son, D.A. (1989) Proc. Natl. Acad. Sci. USA 86, 5104- 
5108. 
[211] Friedman, S.M., Posnett, D.N., Tumang, J.R., Cole, B.C. 
and Crow, M.K. (1991) Arthritis Rheum. 34, 468-480. 
[212] Kappler, J., Kotzin, B., Herron, L., Gelfand, E., Bigler, 
R.D., Boylston, A., Carrel, S., Posnett, D.N., Choi, Y.W. 
and Marrak, P. (1989) Science 244, 811-815. 
[213] Cole, B.C. and Griffiths, M.M. (1993) Arthritis Rheum. 
36, 994-1002. 
[214] Schwab, J.H., Brown, R.R., Anderle, S.K. and Schlievert, 
P.M. (1993) J. Immunol. 150, 4151-4159. 
[215] Friedman, S.M., Crow, M.K., Tumang, J.R., Tumang, M., 
Xu, Y., Hodstev, A.S., Cole, B.C. and Posnett, D.N. 
(1991) J. Exp. Med. 174, 891-900. 
[216] Crow, M.K., Zagon, G., Chu, Z., Ravina, B., Tumang, 
J.R., Cole, B.C. and Friedman, S.M. (1992)Autoimmunity 
14, 23-32. 
[217] Rellahan, B.L., Jones, L.A., Kruisbeek, A.M., Fry, A.M. 
and Matis, L.A. (1990) J. Exp. Med. 172, 1091-1100. 
[218] Hingorani, R., Choi, I.-H., Akolkar, P., Gulwani-Akolkar, 
B., Pergolizzi, R., Silver, J. and Gregersen, P.K. (1993) J. 
Immunol. 151, 5762-5769. 
[219] Wang, X.-H., Ohmen, J.D., Uyemura, K., Rea, T.H., 
Kronenberg, M. and Modlin, R.L. (1993) Proc. Natl. Acad. 
Sci. USA 90, 188-192. 
[220] Posnett, D.N., Sinha, R., Kabak, S. and Russo, C. (1994) J. 
Exp. Med. 179, 609-618. 
[221] Haynes, B.F. and Fauci, A.S. (1987) in Harrison's Princi- 
ples of Internal Medicine, 1 lth Ed., (Braunwald, E., Issel- 
bacher, K.J., Petersdorf, R.G., Wilson, J.D., Martin, J.B. 
and Fauci, A.S., eds.) McGraw-Hill, pp. 328-337. 
[222] Lanzavecchia, A. (1985)Nature 314, 537-539. 
[223] Durie, F.H., Fava, R.A., Foy, T.M., Aruffo, A., Ledbetter, 
J.A. and Noelle, R.J. (1993) Science 261, 1328-1330. 
[224] O'Brien, R.M., Cram, D.S., Coppel, R.L. and Harrison, 
L.C. (1990) J. Autoimmunity 3, 747-757. 
[225] Lafyatis, R., Flipo, R.M., Duquesnoy, B. and Capron, A. 
(1992) Arthritis Rheum. 35, 1016-1027. 
[226] McColl, G.J., Cram, D.S. and Harrison, L.C. (1995)Arthri- 
tis Rheum. 38, 1418-1428. 
[227] Carson, D.A., Chen, P.P. and Kipps, T.J. (1991) J. Clin. 
Invest. 87, 379-383. 
[228] Roosnek, E. and Lanzavecchia, A. (1991) J. Exp. Med. 
173, 487-489. 
[229] Rudolphi, U., Hohlbaum, A., Lang, B., Peter, H.H. and 
Melchers I. (1993) Clin. Exp. Immunol. 92, 404-411. 
[230] Arend, W.P. and Dayer, J.-M. (1990) Arthritis Rheum. 33, 
305-315. 
[231] Miltenburg, A.M.M., Van Laar, J.M., de Kuiper, R., Daha, 
M.R. and Breedveld, F.C. (1992) Scand. J. Immunol. 35, 
603 -610. 
[232] Miossec, P., Naviliat, M., Dupuy, D., Sany, J. and 
Bancherau, J. (1990) Arthritis Rheum. 33, 1180-1187. 
[233] Quayle, A.J., Chromarat, P., Miossec, P., Kjeldsen-Kragh, 
J., Forre, O. and Natvig, J.B. (1993) Scand. J. Immunol. 
38, 75-82. 
[234] Simon, A.K., Seipelt, E. and Sieper, J. (1994) Proc. Natl. 
Acad. Sci. USA 91, 8562-8566. 
[235] Burmester, G.R., Stuhlmiiller, B., Keyszer, G. and Kinne, 
R.W. (1997) Arthritis Rheum. 40, 5-15. 
[236] Wahl, S.M., Hunt, A., Wong, H.L., Dougherty, S., Mc- 
Cartney-Francis, N., Wahl, L.M., Ellingsworth, L., 
Schmidt, J.A., Hall, G., Roberts, A.B. and Sporn, M. 
(1988) J. Immunol. 140, 3026-3031. 
[237] Lacraz, S., Isler, P., Vey, E., Welgus, H.G. and Dayer, 
J.M. (1994) J. Biol. Chem. 269(35), 22027-22033. 
[238] Siegling, A., Kinne, R.W., Buchner, E. and Emmrich, F. 
(1994) Proceedings of 14th European Workshop of 
Rheumatology Research, March 10-12, Gent, Belgium. 
[239] Miissener, A., Klareskog, L., Lorentzen, J.C. and Kleinau, 
S. (1995) Scand. J. Immunol. 42, 128-134. 
[240] Stiinkel, K.G., Theisen, P., Mouzaki, A., Diamantstein, T. 
and Schlumberger, H.D. (1988) Immunology 64, 683-689. 
[241] Meacock, S.C., Brandon, D.R. and Billingham, M.E.J. 
(1994) Ann. Rheum. Dis. 53, 653-658. 
[242] Mikecz, K. and Giant, T.T. (1994) Arthritis Rheum. 37, 
1395-1403. 
[243] Kelso, A. (1995) Immunol. Today 16, 374-379. 
[244] Kotzin, B.L., Strober, S., Engelman, E.G., Calin, A., 
Hoppe, R.T., Kansas, G.S., Terrell, C.P. and Kaplan, H.S. 
(1981) N. Engl. J. Med. 305, 969-976. 
[245] Trentham, D.E., Belli, J.A., Anderson, R.J., Buckley, J.A., 
Goetzl, E.J., David, J.R. and Austen, K.F. (1981) N. Engl. 
J. Med. 305, 676-682. 
[246] Strober, S., Tanay, A., Field, E., Hoppe, R.T., Calin, A., 
Engleman, E.G., Kotzin, B., Brown, B.W. and Kaplan, 
H.S. (1985) Ann. Int. Med. 102, 441-449. 
R. W. Kinne et al. / Biochimica et Biophysica Acta 1360 (1997) 109-141 139 
[247] 
[248] 
[249] 
[250] 
[251] 
[252] 
[253] 
[254] 
[255] 
[256] 
[257] 
[258] 
[259] 
[260] 
[261] 
[262] 
[263] 
[264] 
[265] 
[266] 
[267] 
[268] 
[269] 
[270] 
[271] 
Schurman, D.J., Hirshman, P.H. and Strober, S. (1981) 
Arthritis Rheum. 24, 38-44. 
Watson, W.C., Tooms, R.E., Carnesale, P.G. and 
Dutkowsky, J.P (1994) Clin. Immunol. Immunopathol. 73, 
27-37. 
Tomita, T., Kashiwagi, N., Shimaoka, Y., Ikawa, T., Tan- 
abe, M., Nakagawa, S., Kawamura, S., Denno, K., Owaki, 
H. and Ochi, T. (1994) J. Rheumatol. 21, 1608-1614. 
Hirohata, S., Yanagida, T., Itoh, K., Nakamura, H., 
Yoshino, S., Tomita, T. and Ochi, T. (1996) Arthritis 
Rheum. 39, 836-843. 
Billingham, M.E.J. (1995) in Mechanisms and Models in 
Rheumatoid Arthritis (Henderson, B., Edwards, J.C.W. and 
Pettipher, E.R., eds.) pp. 389, Academic Press. 
Mountz, J.D., Wu, J., Cheng, J. and Zhou, T. (1994) 
Arthritis Rheum. 37, 1415-1420. 
Kohashi, O., Aihara, K., Ozawa, A., Kotani, S. and Azuma, 
I. (1982) Lab. Invest. 47, 27-36. 
Allen, J.B., Malone, D.G., Wahl, S.M., Calandra, G.B. and 
Wilder, R.L. (1985) J. Clin. Invest. 76, 1042-1056. 
Cohen, I.R., Holoshitz, J., Van Eden, W. and Frenkel, A. 
(1985) Arthritis Rheum. 28, 841-845. 
Myers, L.K., Stuart, J.M. and Kang, A.H. (1989) J. Im- 
munol. 143, 3976-3980. 
Cohen, I.R. (1991) Annu. Rev. Immunol. 9, 567-589. 
Yang, X.-d., Gasser, J. and Feige, U. (1990) Clin. Exp. 
Immunol. 81, 189-194. 
Anderton, S.M., Van der Zee, R., Prakken, B., Noordzij, 
A. and Van Eden W. (1995) J. Exp. Med. 181,943-952. 
Miller, A., A1-Sabbagh, A., Santos, L.M.B., Prabhu Das, 
M. and Weiner, H.L. (1993)J. Immunol. 151, 7307-7315. 
Weiner, H.L., Mackin, G.A., Matsui, M., Orav, J.E., 
Khoury, S.J., Dawson, D.M. and Hafler, D.A. (1993) 
Science 259, 1321-1324. 
Firestein, G.S., Yeo, M. and Zvaifler, N. (1995) J. Clin. 
Invest. 96, 1631-1638. 
Sack, U., Kuhn, H., Ermann, J., Kinne, R.W., Vogt, S., 
Jungmichel, H. and Emmrich, F. (1994) J. Rheumatol. 21, 
10-16. 
Firestein, G.S. (1996) Arthritis Rheum. 39, 1781-1790. 
Schaible, U.E., Wallich, R., Kramer, M.D., Nerz, G., 
Stehle, T., Museteanu, C. and Simon, M.M. (1994) Int. 
Immunol. 6, 671-681. 
Moreland, L.W., Heck, L.W. Jr., Sullivan, W., Pratt, P.W. 
and Koopman, W.J. (1993) Am. J. Med. Sci. 305, 40-51. 
Paulus, H.E., Machleder, H.I., Levine, S., Yu, D.T.Y. and 
MacDonald, N.S. (1977) Arthritis Rheum. 20, 1249-1262. 
Karsh, J., Klippel, J.H., Plotz, P.H., Decker, J.L., Wright, 
D.G. and Flye, M.W. (1981) Arthritis Rhem. 24, 867-873. 
Wallace, D., Goldfinger, D., Lowe, C., Nichols, S., Weiner, 
J., Brachman, M. and Klineberg, J.R. (1982) N. Engl. J. 
Med. 306, 1406-t410. 
Larsson, P., Holmdahl, R., Dencker, L. and Klareskog, L. 
(1985) Immunology 56, 383-391. 
Weinblatt, M.E., Maddison, P.J., Bulpitt, K.J., Hazleman, 
B.L., Urowitz, M.B., Sturrock, R.D., Coblyn, J.S., Maier, 
A.L., Spreen, W.R., Manna, V.K. and Johnston, J.M. 
(1995) Arthritis Rheum. 38, 1589-1594. 
[272] Schreiber, S.L., Crabtree, G.R. (1992) Immunol. Today 13, 
136-142. 
[273] Bretscher, P.A. and Havele, C. (1992) Eur. J. Immunol. 22, 
349-355. 
[274] Brooks, P.M. (1992) Curr. Opin. Rheumatol. 4, 309-313. 
[275] Yocum, D.E., Klippel, J.H., Wilder, R.L., Gerber, N.L., 
Austin, H.A., Wahl, S.M., Lesko, L., Minor, J.R., Preuss, 
H.G., Yarboro, C., Berkebile, C. and Dougherty, S. (1988) 
Ann. Intern. Med. 109, 863-869. 
[276] Tugwell, P., Bombardier, C., Gent, M., Bennett, K., 
Bensen, W., Carette, S., Chalmers, A., Esdaile, J., Kleinoff, 
A., Kragg, G., Ludwin, D. and Roberts, R. (1990) Lancet 
335, 1051-1055. 
[277] Forre, O. and the Norwegian Arthritis Group (1994) Arthri- 
tis Rheum. 37, 1506-1512. 
[278] Pasero, G., Priolo, F., Marubini, E., Fantini, F., Ferraccioli, 
G, Magaro, M., Marcolongo, R., Oriente, P., Pipitone, V., 
Portioli, I., Tirri, G., Trotta, F. and Della Casa Alberighi, 
O. (1996) Arthritis Rheum. 39, 1006-1015. 
[279] Muraoka, K.-I., Fujimoto, K., Sun, X., Yoshioka, K., 
Shimizu, K.-I., Yagi, M., Bose, H. Jr., Miyazaka, I. and 
Yamamoto, K.-I. (1996) J. Clin. Invest. 97, 2433-2439. 
[280] Yocum, D.E., Allen, J.B., Wahl, S.M., Calandra, G.B. and 
Wilder, R.L. (1986) Arthritis Rheum. 29, 262-273. 
[281] Banerjee, S.J., Wei, B.Y., Hillman, K., Luthra, H.S. and 
David, C.S. (1988)J. Immunol. 141, 1150-1154. 
[282] Kyle, V., Coughlan, R.J., Tighe, H., Waldmann, H. and 
Hazleman, B.L. (1989) Ann. Rheum. Dis. 48, 428-429. 
[283] Bacha, P., Forte, S.E., Perper, S.J., Trentham, D.E. and 
Nichols, J.C. (1992) Eur. J. Immunol. 22, 1673-1679. 
[284] Sewell, K.L., Parker, K.C., Woodworth, T.G., Reuben, J., 
Swartz, W. and Trentham, D.E. (1993) Arthritis Rheum. 
36, 1223-1233. 
[285] Haqqi, T.M., Qu, X.-M., Anthony, D., Ma, J. and Sy, 
M.-S. (1996) J. Clin. Invest. 97, 2849-2858. 
[286] Acha-Orbea, H., Mitchell, D.J., Timmermann, L., Wraith, 
D.C., Tausch, G.S., Waldor, M.K., Zamvil, S.S., McDevitt, 
H.O. and Steinman, L. (1988) Cell 54, 263-273. 
[287] Urban, J.L., Kumar, V., Kono, D.H., Gomez, C., Horvath, 
S.J., Clayton, J., Ando, D.G., Sercaz, E.E. and Hood, L. 
(1988) Cell 54, 577-592. 
[288] Yoshino, S., SchlipkiSter, E., Kinne, R.W., Hiinig, T. and 
Emmrich, F. (1990) Eur. J. Immunol. 20, 2805-2808. 
[289] Yoshino, S., Cleland, L.G. and Mayrhofer, G. (1991) 
Arthritis Rheum. 34, 1039-1047. 
[290] Yoshino, S., Cleland, L.G., Mayrhofer, G., Brown, R.R. 
and Schwab, J.H. (1991) J. Immunol. 146, 4187-4189. 
[291] Yoshino, S. and Yoshino, J. (1992) Cell. Immunol. 144, 
382-391. 
[292] Pelegri, C., Kiihnlein, P., Buchner, E., Schmidt, C.B., 
Franch, A., Castell, M., Hiinig, T., Emmrich, F. and Kinne, 
R.W. (1996) Arthritis Rheum. 39, 204-215. 
[293] Peterman, G.M., Spencer, C., Sperling, A.I. and Bluestone, 
J.A. (1993) J. Immunol. 151, 6546-6558. 
140 R.W. Kinne et al. / Biochimica et Biophysica Acta 1360 (1997) 109-141 
[294] 
[295] 
[296] 
[297] 
Ranges, G.E., Sriram, S. and Cooper, S.M. (1985) J. Exp. 
Med. 162, 1105-1110. 
Milton, A.W., Kinne, R.W., Vorderwiilbecke, U. and 
Emmrich, F. (1991) Arthritis Rheum. 34(S), 68. 
Hutchings, P.R., Cooke, A., Dawe, K., Waldmann, H. and 
Roitt, I.M. (1993) Eur. J. Immunol. 23, 965-968. 
Herzog, C., Walker, C., Miiller, C., Rieber, P., Reiter, C., 
Riethmiiller, G., Wassmer, P., Stockinger, H., Madic, O. 
and Pichler, W.J. (1989) J. Autoimmunity 2, 627-642. 
[298] Goldberg, D., Morel, P., Chatenoud, L., Boitard, C., 
Menkes, C.J., Bertoye, P.H., Revillard, J.P. and Bach, J.F. 
(1991) J. Autoimmunity 4, 617-630. 
[299] Reiter, C., Kakavand, B., Rieber, E.P., Schattenkirchner, 
M., Riethmiiller, G. and Kriiger, K. (1991) Arthritis Rheum. 
34, 525-536. 
[300] Wendling, D., Racadot, E., Morel-Fourrier, B. and Wij- 
denes, J. (1992) Clin. Rheumatol. 11, 542-547. 
[301] Moreland, L.W., Bucy, R.P., Tilden, A., Pratt, P.W., 
LoBuglio, A.F., Khazali, M., Everson, M.P., Daddona, P., 
Ghrayeb, J., Kilgarriff, C., Sanders, M.E. and Koopman, 
W.J. (1993) Arthritis Rheum. 36, 307-318. 
[302] Van der Lubbe, P.A., Reiter, C., Breedveld, F.C., Kriiger, 
K., Schattenkirchner, M., Sanders, M.E. and Riethmi~ller, 
G. (1993) Arthritis Rheum. 36, 1375-1379. 
[303] Tak, P.P., Van der Lubbe, P.A., Cauli, A., Daha, M.R., 
Smeets, T.J.M., Kluin, P.M., Meinders, A.E., Yanni, G., 
Panayi, G.S. and Breedveld, F.C. (1995) Arthritis Rheum. 
38, 1457-1465. 
[304] Van der Lubbe, P.A., Dijkmans, B.A.C., Markusse, H.M., 
N~issander, V. and Breedveld, F.C. (1995) Arthritis Rheum. 
38, 1097-1106. 
[305] Levy, R., Weisman, M., Wiesenhutter, C., Yocum, D., 
Schnitzer, T., Goldman, A., Schiff, M., Breedveld, F.C., 
Solinger, A., McDonald, B. and Lipani, J. (1996) Arthritis 
Rheum. 39(S), 122. 
[306] Panayi, G.S., Choy, E.H.S., Connolly, D.J.A., Regan, T., 
Manna, V.K., Rapson, N., Kingsley, G.H. and Johnston, 
J.M. (1996) Arthritis Rheum. 39(S), 244. 
[307] Epstein, W.V. (1996) Arthritis Rheum. 39, 1773-1780. 
[308] Choy, E.H.S., Pitzalis, C., Cauli, A., Bijl, J.A., Schantz, 
A., Woody, J., Kingsley, G.H. and Panayi, G.S. (1996) 
Arthritis Rheum. 39, 52-56. 
[309] Tsygankov, A.Y., Br~ker, B.M., Guse, A.H., Meinke, U., 
Roth, E., Rossman, C. and Emmrich, F. (1993) J. Leukoc. 
Biol. 54, 430-438. 
[310] Bri3ker, B.M., Tsygankov, A.Y., Fickenscher, H., Chitaev, 
N.A., Mtiller-Fleckenstein, I., Fleckenstein, B., Bolen, 
J.B. and Emmrich, F. (1994) Eur. J. Immunol. 24, 843-850. 
[311] Jonker, M. and Den Brok, J.H.A.M. (1987) Eur. J. Im- 
munol. 17, 1547-1553. 
[312] Schmidt, C.B., Buchner, E., Lehman, M., Franch, A., 
Billingham, M.E.J., Castell, M., Emmrich, F. and Kinne, 
R.W. (1994) Proceedings of European Conference on 
Therapeutic Immunomodulation, September 3-6, Le Bis- 
chenberg, France. 
[313] Baldari, C., Milia, E., Di Somma, M.M., Baldoni, F., 
Valitutti, S. and Telford, J.L. (1995) Eur. J. Immunol. 25, 
1843-1850. 
[314] Gudmundsson, S., R~nnelid, J., Karlsson-Parra, A., 
Lysholm, J., GudbfiSrnsson, B., Widenfalk, B., Janson, 
C.H. and Klareskog, L. (1992) Scand. J. Immunol. 36, 
681-688. 
[315] Pelegri, C., Morante, M.P., Castellote, C., Castell, M. and 
Franch, A. (1995) Cell. Immunol. 165, 177-182. 
[316] Br~iuer, R., Wutzler, U., Schreiter, A., Henzgen, S., Petrow, 
P.K., Thoss, K. and Katenkamp, D. (1994) Proceedings of 
the 12 th European Immunology Meeting, 14-17 June, 
Barcelona, Spain. 
[317] Issekutz, T.B., and Issekutz, A.C. (1991) Clin. Immunol. 
Immunopathol. 61,436-447. 
[318] Elices, M.J., Tsai, V., Strahl, D., Goel, A.S., Tollefson, V., 
Arrhenius, T., Wayner, E.A., Gaeta, F.C.A., Fikes, J.D. 
and Firestein, G.S. (1994) J. Clin. Invest. 93, 405-416. 
[319] Van de Langerijt, A.G., Volsen, S.G., Hicks, C.A., Craig, 
P.J., Billingham, M.E. and Van den Berg, W.B. (1994) 
Immunology 81,414-419. 
[320] Kinne, R.W., Schmidt-Weber, C.B., Hoppe, R., Buchner 
E., Palombo-Kinne, E., Niimberg, E. and Emmrich, F. 
(1995) Arthritis Rheum. 38, 1777-1790. 
[321] Feldmann, M., Brennen, F.M., Elliott, M., Katzikis, P. and 
Maini, R.N. (1994)Circul. Shock 43, 179-184. 
[322] Finkelman, F.D. (1995) J. Exp. Med. 182, 279-282. 
[323] Racke, M.K., Bonomo, A., Scott, D.E., Cannella, B., 
Levine, A., Raine, C.S., Shevach, E.M. and Rbcken, M. 
(1994) J. Exp. Med. 180, 1961-1966. 
[324] RiScken, M., Urban, J.F. and Shevach, E.M. (1994) J. Exp. 
Med. 179, 1885-1893. 
[325] Friedman, A. and Weiner, H.L. (1994) Proc. Natl. Acad. 
Sci. USA 91, 6688-6692. 
[326] Trentham, D.E., Dynesius-Trentham, R.A., Orav, E.J., 
Combitchi, D., Lorenzo, C., Sewell, K.L., Hailer, D.A. and 
Weiner, H.L. (1993) Science 261, 1727-1730. 
[327] Sieper, J., Karym S., S~3rensen, H., Alten, R., Eggens, U., 
Htige, W., Hiepe, F., Kiihne, A., Listing, J., Ulbrich, N., 
Braun, J., Zink, A. and Mitchison, N.A. (1996) Arthritis 
Rheum. 39, 41-51. 
[328] Chen, Y., Kuchroo, V.K., Inobe, J.-i., Hafler, D.A, and 
Weiner, H.L. (1994) Science 265, 1237-1240. 
[329] Yoshino, S., Quattrocchi, E. and Weiner, H.L. (1995) 
Arthritis Rheum. 38, 1092-1096. 
[330] Tian, J., Atkinson, M.A., Clare-Salzler, M., Herschenfeld, 
A., Forsthuber, T., Lehmann, P.V. and Kaufman, D.L. 
(1996) J. Exp. Med. 183, 1561-1567. 
[331] Nicholson, L.B., Greet, J.M., Sobel, R.A., Lees, M.B. and 
Kuchroo, V.K. (1995) Immunity 3, 397-405. 
[332] Brocke, S., Gijbels, K., Allegretta, M., Ferber, I., Piercy, 
R. W. Kinne et al. / Biochimica et Biophysica Acta 1360 (1997) 109-141 141 
[333] 
[334] 
[335] 
[3361 
[337] 
C., Blankenstein, T., Martin, R., Utz, U., Karin, N., 
Mitchell, D., Veromaa, T., Waisman, A., Gaur, A., Con- 
Ion, P., Ling, N., Fairchild, P.J., Wraith, D.C., O"Garra, 
A., Fathman, C.G. and Steinman, L. (1996) Nature 379, 
343-346. 
Zhang, J., Medaer, R., Stinissen, P., Hailer, D. and Raus, J. 
(1993) Science 261, 1451-1454. 
Boissier, M.-C., Chiocchia, G., Bessis, N., Hajnal, J., 
Garotta, G., Nicoletti, F. and Fournier, C. (1995) Eur. J. 
Immunol. 25, 1184-1190. 
Allen, J.B., Wong, H.L., Costa, G.L., Bienkowski, M.J. 
and Wahl, S.M. (1993) J. Immunol. 151, 4344-4351. 
Hughes, C., Wolos, J.A., Giannini, E.H. and Hirsch, R. 
(1994) J. Immunol. 153, 3319-3325. 
De Wit, D., Van Mechelen, M., Ryelandt, M., Figuereido, 
A.C., Abramowicz, D., Goldman, M., Bazin, H., Urbain, J. 
and Leo, O. (1994) J. Exp. Med. 175, 9-14. 
[338] Lenschow, D.J., Zeng, Y., Thistlehwaite, J.R., Montag, A., 
Brady, W., Gibson, M.G., Linsley, P.S. and Bluestone, 
J.A. (1992) Science 257, 789-792. 
[339] Brecht, B. "Der verwundete Sokrates", in Gesammelte 
Werke, Suhrkamp Verlag, Frankfurt am Main, Germany 
(1967). 
[340] Chattopadhyay, C., Chattopadhyay, H., Natvig, J.B., 
Michaelsen, T.E. and Mellbye, O.J. (1979) Scand. J. Im- 
munol. 10, 309-316. 
[341] Emery, P., Gentry, K.C., Mackay, I.R., Muirden, K.D. and 
Rowley, M. (1987) Arthritis Rheum. 30, 849-856. 
[342] Klareskog, L., Forsum, U., Scheyniers, A., Kabelitz, D. 
and Wigzell, H. (1982) Proc. Natl. Acad. Sci. USA 79, 
3632-3636. 
[343] Potocnik, A.J., Kinne, R., Menninger, H., Zacher, J., 
Emmrich, F. and Kroczek, R.A. (1990) Scand. J. Immunol. 
31,213-224. 
[344] Hemler, M.E., Glass, D., Coblyn, J.S. and Jacobson, J.G. 
(1986) J. Clin. Invest. 78, 696-702. 
[345] Potocnik, A.J., Menninger, H., Yang, S.Y., Priner, K., 
Krause, A., Burmester, G.R., BriSker, B.M., Hept, P., 
Weseloh, G., Michels, H., Emmrich, F. and Kroczek, R.A. 
(1991) Scand. J. Immunol. 34, 351-358. 
[346] Boussiotis, V.A., Freeman, G.J., Griffin, J.D., Gray, G.S.. 
Gribben, LG. and Nadler, L.M. (1994) 180, 1665-1673. 
[347] Freimark, B., Lanier, L., Phillips, J, Quertermous, T. and 
Fox, R. (1987) J. Immunol. 138, 1724-1729. 
[348] Savill, C.M., Delves, P.J., Kioussis, D., Walker, P., Lyd- 
yard, P.M., Colaco, B., Shipley, M. and Roitt, I.M. (1987) 
Scand. J. Immunol. 25, 629-635. 
[349] Keystone, E.C., Minden, M., Klock, R., Poplonski, L., 
Zalcberg, J., Takadera, T. and Mak, T.W. (1988) Arthritis 
Rheum. 31, 1555-1557. 
[350] Duby, A.D., Sinclair, A.K., Osborne-Lawrence, S.L., 
Zeldes, W., Kan, L. and Fox, D.A. (1989) Proc. Natl. 
Acad. Sci. USA 86, 6206-6210. 
[351] Sioud, M., Kjetdsen-Kragh, J., Quayle, A., Kalvenes, C., 
Waalen, K., Forte, O. and Natvig, 3.B. (1990) Scand. J. 
Immunol. 31,415-421. 
[352] Andreu, J.L., Trujillo, A., Alonso, J.M., Mulero, J. and 
Martinez-A, C. (1991) Arthritis Rheum. 34, 808-814. 
[353] Van Laar, J.M., Miltenburg, A.M.M., Verdonk, M.J.A., 
Daha, M.R., De Vries, R.R.P., Van den Elsen, P.J. and 
Breedveld, F.C. (1991) Clin. Exp. Immunol. 83, 352-358. 
[354] Doherty, P.3., Yang, S.X., Laxer, R.M., Silverman, E.D., 
Inman, R. and Pan, S. (1992) 3. Immunol. 149, 295-299. 
[355] Hylton, W., Smith-Burchnell, C., Pelton, B.K., Palmer, 
R.G., Denman, A.M. and Malkovsky, M. (1992) Br. J. 
Rheumatol. 31, 55-57. 
[356] Olive, C., Gatenby, P.A. and Serjeantson, S.W. (1992)Eur. 
J. Immunol. 22, 2587-2593. 
[357] Davey, M.P. and Munkirsm, D.D. (1993) Clin. Immunol. 
Immunopathol. 68, 79-87. 
[358] Struyk, L. (1993) Hum. Immunol. 37, 237-251. 
[359] Karim, S.N., Murphy, E.A., Sturrock, R.D. and Goudie, 
R.B. (1995) Br. J. Rheumatol. 34, 232-235. 
[360] Fugger, L., Rothbard, J.B. and Sonderstrup-McDevitt, G. 
(1996) Eur. J. Immunol. 26, 928-933. 
